前立腺癌と男性骨粗鬆症―最新骨管理マニュアル　改訂第2版

出版社： 医学図書出版
著者：
発行日： 2015-10-27
分野： 臨床医学：外科  >  泌尿器科学
ISBN： 9784865171365
電子書籍版： 2015-10-27 （改訂第2版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,475 円(税込)

購入する

目次

  • 前立腺癌と男性骨粗鬆症―最新骨管理マニュアル　改訂第2版

    ―目次―

    I. 男性骨粗鬆症の診療
    　1．男性骨粗鬆症の臨床的特徴
    　2．男性骨粗鬆症の病態生理
    　3．LOH症候群と骨粗鬆症
    　4．男性骨粗鬆症の診断
    　5．骨折リスクとその評価ならびに薬物治療の開始基準
    　6．夜間頻尿と転倒リスク
    　7．骨代謝マーカーの活用
    　8．骨粗鬆症治療薬の特徴と男性骨粗鬆症におけるエビデンス

    II. ステロイド性骨粗鬆症の特徴と管理

    III. 前立腺癌骨管理アルゴリズム
    　　　―レベル1エビデンスに準拠した薬剤選択の提言―

    IV. 骨転移病変の病態と診断
    　1．前立腺癌造骨性骨転移のメカニズム
    　2．核医学検査を用いた前立腺癌骨転移の診断
    　3．骨転移診断におけるPET／CT
    　4．BMAの有害事象
    　　　―顎骨壊死およびBMAを投与されている患者に対する
    　　　　歯科側の対応―
    　5．骨代謝マーカーの骨転移診断への応用
    　6．Bone scan index

    V. 骨転移病変の治療
    　1．メタストロン注射
    　2．ラジウム-223
    　3．放射線治療
    　4．外科的治療

    VI. 診療科横断的な骨転移診療体制
    　　　―東京大学病院骨転移キャンサーボード―

    VII．前立腺癌と地域医療連携

    VIII. 骨転移診療ガイドラインについて

    IX．多職種で取り組む骨粗鬆症診療
    　　　―骨粗鬆症リエゾンサービスの意義と実践―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 男性骨粗鬆症の診療

P.6 掲載の参考文献
1) Gullberg B, Johnell O, Kanis JA : Worldwide projections for hip fracture. Osteoporos Int 7 : 407-413, 1997
PubMed
2) Smith EP, Boyd J, Frank GR, et al : Estrogen resistance caused by a mutation in the estrogen-receptor gene in man. N Engl J Med 331 : 1056-1061, 1994
 
3) Morishima A, Grumbach MM, Simpson ER, et al : Aromatase deficiency in male and female siblings caused by a novel mutation in the physiological role of estrogens. J Clin Endocrinol Metab 80 : 3689-3698, 1995
PubMed
4) Kawano H, Sato T, Yamada T, et al : Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100 : 9416-9421, 2003
PubMed
5) Seeman E : Growth in bone mass and size are racial and gender differences in bone mineral density are more apparent than real? J Clin Endocrinol Metab 83 : 1414-1419, 1998
 
6) Seeman E : Pathogenesis of osteoporosis. J Appl Physiol 95 : 2142-2151, 2003
 
7) Kanis JA, Johnell O, Oden A, et al : Epidemiology of Osteoporosis and Fracture in Men. Calcif Tissue Int 75 : 90-99, 2004
PubMed
8) Szulc P, Delmas PD : Biochemical markers of bone turnover in men. Calcif Tissue Int 69 : 229-234, 2004
 
9) Riggs BL, Melton LJ, Robb RA, et al : A population-based assessment of rates of bone loss at multiple skeletal sites : evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 23 : 205-214, 2008
 
10) Seeman E : The Growth and Age-Related Origins of Bone Fragility in Men. Calcif Tissue Int 75 : 100-199, 2004
PubMed
11) Burge R, Dawson-Hughes B, Solomo DH, et al : Incidence and economic burden of osteoporosis-related fractures in the United States. J Bone Miner Res 22 : 465-475, 2007
 
12) Bliuc D, Nguyen ND, Milch VE, et al : Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301 : 513-521, 2009
PubMed
13) Johnell O, Kanis JA : An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17 : 1726-1733, 2006
PubMed
14) Memon A, Pospula WM, Tantawy AY, et al : Incidence of hip fracture in Kuwait. Int J Epidemiol 27 : 860-865, 1998
PubMed
15) Maggi S, Kelsey JL, Livtak J, et al : Incidence of hip fractures in the elderly : a cross-national analysis. Osteoporos Int 1 : 232-241, 1991
 
16) 八重樫由美, 坂田清美, 他 : 大腿骨近位部骨折の発生率にブレーキ. Medical Tribune Vol.47, No.45 2014年11月6日
 
17) Herrera A, Martinez AA, Ferrandez L, et al : Epidemiology of hip fracture in Spain. Int Orthop 30 : 11-14, 2006
PubMed
18) Chang KP, Center JR, Nguyen TV, et al : Incidence of hip and other osteoporotic fractures in elderly men and women : Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 19 : 532-536, 2004
 
19) Yoshimura N, Kinoshita H, Danjoh S, et al : Prevalence of vertebral fractures in a rural Japanese population. J Epidemiol 5 : 171-175, 1995
 
20) Fujiwara S, Kasagi F, Masunari N, et al : Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18 : 1547-1553, 2003
PubMed
21) Hagino H, Yamamoto K, Oshiro H, et al : Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori prefecture, Japan. Bone 24 : 265-270, 1999
 
22) 重信恵一, 橋本友幸, 大越康充, 他 : 当科における男性骨粗鬆症患者の臨床像と治療について. Osteoporosis Jpn 13 : 160, 2005
 
23) 白木正孝 : 男性骨粗鬆症の多様性. Osteoporosis Jpn 11 (Suppl. 1) : 76, 2003
 
24) 福永仁夫, 曽根照喜 : 続発性骨粗鬆症-臨床の立場から-男性の骨粗鬆症. 骨粗鬆症治療 4 : 150-154, 2005
 
25) Amin S, Felson DT : Osteoporosis in men. Rheum Dis Clin North Am 27 : 19-47, 2001
 
26) Forsen L, Sogaard AJ, Meyer HE, et al : Survival after hip fracture : short- and long-term excess mortality according to age and gender. Osteoporos Int 10 : 73-78, 1999
 
27) Haentjens P, Magziner J, Colon-Emeric CS, et al : Meta-analysis : excessmortality after hip fracture among older women and men. Ann Intern Med 152 : 380-390, 2010
 
28) Jiang HX, Majumdar SR, Dick DA, et al : Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20 : 494-500, 2005
PubMed
29) Sembo I, Johnell O : Consequences of a hip fracture. A prospective study over 1 year. Osteoporos Int 3 : 148-153, 1993
 
30) Jensen JS, Bagger J : Long-term social prognosis after hip fractures. Acta Orthop Scand 53 : 97-101, 1982
PubMed
P.14 掲載の参考文献
1) van Staa TP, Dennison EM, Leufkens HG, et al : Epidemiology of fractures in England and Wales. Bone 29 : 517-522, 2001
PubMed
2) Watts NB, Adler RA, Bilezikian JP, et al : Endocrine Society : Osteoporosis in men : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97 : 1802-1822, 2012
PubMed
3) Riggs BL, Melton LJ, Robb RA, et al : A population-based assessment of rates of bone loss at multiple skeletal sites : evidence for substantial trabecular bone loss in young adultwomen and men. J Bone Miner Res 23 : 205-214, 2008
 
4) Riggs BL, Melton Iii LJ 3rd, Robb RA, et al : Population-based study of age and sex differences in bone volumetric density size, geometry, and structure at different skeletal sites. J Bone Miner Res 19 : 1945-1954, 2004
 
5) Stoch SA, Parker RA, Chen L, et al : Bone lossin men wiyh prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86 : 2787-2791, 2001
 
6) Mittan D, Lee S, Miller E, et al : Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 : 3656-3661, 2002
PubMed
7) Mellstrom D, Johnell O, Ljunggren O, et al : Free testosterone in an independent predictoe of BMD and prevalent fractures in elderly men : MrOS Sweden. J bone Miner Res 21 : 529-535, 2006
 
8) Orwoll E, Lambert LC, Marshall LM, et al : Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 166 : 2124-2131, 2006
PubMed
9) Hyde Z, Flicker L, Almeida OP, et al : Low free testosterone predicts frailty in older men : the health in men study. J Clin Endocrinol Metab 95 : 3165-3172, 2010
PubMed
10) Van Pottelbergh I, Goemaere S, Kaufman JM : Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88 : 3075-3081, 2003
 
11) Koudu Y, Onouchi T, Hosoi T, et al : Association of CYP19 gene polymorphism with vertebral fractures in Japanese postmenopausal women. Biochem Genet 50 : 389-396, 2012
PubMed
12) Giustina A, Mazziotti G, Canalis E : Growth hormone insulin-like growth factors, and the skelton. Endocr Rev 29 : 535-559, 2008
 
13) Colao A, Di Somma C, Pivonello R, et al : Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocr Metab 84 : 1919-1924, 1999
 
14) Melhus H, Snellman G, Gedeborg R, et al : Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden study. J Clin Endocrinol Metab 95 : 2637-2645, 2010
 
15) Chavassieux PM, Chenu C, Valentin-Opran A, et al : Influence of experimental conditions on osteoblast activity in human primary bone cell cultures. J Bone Miner Res 5 : 337-343, 1990
PubMed
16) Roholl PJ, Blauw E, Zurcher C, et al : Evidence for a diminished maturation of preosteoblasts into osteoblasts during aging in rats : an ultrastructural analysis. J Bone Miner Res 9 : 355-366, 1994
PubMed
17) Kveiborg M, Kassem M, Langdahl B, et al : Telomere shortening during of human osteoblasts in vitro and leukocytes in vivo : lack of excessive telomere loss in osteoporotic patients. Mech Ageing Dev 106 : 261-271, 1999
PubMed
18) Koshihara Y, Hirano M, Kawamura M, et al : Mineralization ability of cultured human osteoblast-like periosteal cells does not decline with aging. J Gerontol 46 : B201-206, 1991
 
19) Callaci JJ, Himes R, Lauing K, et al : Binge alcohol-induced bone damage is accompanied by differential expression of bone remodeling-related genes in rat vertebral bone. Calif Tissues Int 84 : 474-484, 2009
 
20) Maurel DB, Boisseau N, Benhamou CL, et al : Alcohol and bone : review of dose effects and mechanisms. Osteoporos Int 23 : 1-16, 2012
PubMed
21) Hofbauer LC, Rauner M : Minireview : live and let die : molecular effects of glucocorticoids on bone cells. Mol Endocrinol 23 : 1525-1531, 2009
 
22) Tamura Y, Araki A, Chiba Y, et al : Remarkable increase in lumbar spine bone mineral density and ameriolation in biochemical markers of bone turnover after parathyroidectomy in elderly primary hyperparathyroidism. J Bone Miner Metab 25 : 226-231, 2007
 
23) Nicodemus KK, Folsom AR : Iowa Women's Health Study : Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24 : 1192-1197, 2001
PubMed
24) Bonds DE, Larson JC, Schwartz AV, et al : Risk of fracture in women with type 2 diabetes : the Women's Health Initiative Observational Study. J Clin Endocr Metab 91 : 3404-3410, 2006
PubMed
25) Chen YY, Cheng PY, Wu SL, et al : Parkinson's disease and risk of hip fracture : an eight year follow-up study in Taiwan. Parkinsonis Rel Disord 18 : 506-509, 2012
 
P.22 掲載の参考文献
1) 厚生労働省大臣官房統計情報部 : 平成19年国民生活基礎調査の概況. 厚生労働省. 東京, 2007
 
2) 骨粗鬆症の予防と治療ガイドライン作成委員会 : 骨粗鬆症の予防と治療ガイドライン 2011年版. 東京, 2011
 
3) Kawano H, Sato T, Yamada T, et al : Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A 100 : 9416-9421, 2003
PubMed
4) Scherr D, Pitts WR Jr, Vaughan ED : Diethylstilbesterol revisited : androgen deprivation, osteoporosis and prostate cancer. J Urol 167 : 535-538, 2002
 
5) Vermeulen A, Kaufman JM, Giagulli VA : Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 81 : 1821-1826, 1996
PubMed
6) Riggs BL, Khosla S, Melton LJ 3rd : Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23 : 279-302, 2002
PubMed
7) 岩本晃明, 柳瀬敏彦, 並木幹夫, 他 : 日本人成人男子の総テストステロン, 遊離テストステロンの基準値の設定. 日泌会誌 95 : 751-760, 2004
 
8) 白木正孝, 曽根照喜, 福永仁夫 : 男性骨粗鬆症の診断基準. Bone 15 : 255-260, 2001
Medical*Online
9) Smith MR : Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol 172 : S52-53, 2004
PubMed
10) Daniell HW : Osteoporosis after orchictomv for prostate cancer. J Urol 157 : 439-444, 1997
PubMed
11) Orwoll E, Ettinger M, Weiss S, et al : Alendronate for the treatment of osteoporosis. N Engl J Med 343 : 604-610, 2000
PubMed
12) Ringe JD, Faber H, Dorst A : Alendronate treatment of established primary osteoporosis in men : results of a 2-year prospective study. J Clin Endocrinol Metab 86 : 5252-5255, 2001
PubMed
13) Isidori AM, Giannetta E, Greco EA, et al : Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle age men : a meta-analysis. Clin Endocrinol 63 : 280-293, 2005
 
14) Orwoll E, Lambert LC, Marshall LM, et al : Endogenous testosterone levels, physical performance, and fall risk in older man. Arch Intern Med 23 : 2124-2131, 2006
 
15) Bhasin S : Testosterone supplementation for aging-associated sarcopenia. J Gerontol A Biol Sci Med Sci 58 : 1002-1008, 2003
PubMed
16) Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, et al : Androgen treatment and muscle strength in elderly men : A meta-analysis. J Am Geriatr Soc 54 : 1666-1673, 2006
 
17) Snyder PJ, Peachey H, Hannoush P, et al : Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84 : 2647-2653, 1999
 
18) Smith MR, Finkelstein JS, McGovern FJ, et al : Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87 : 599-603, 2002
PubMed
19) Tenover JS : Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75 : 1092-1098, 1992
PubMed
20) Meier C, Nguyen TV, Handelsman DJ, et al : Endogenous sex hormones and incident fracture risk in older men : the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 168 : 47-54, 2008
PubMed
21) Amory JK, Watts NB, Easley KA, et al : Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89 : 503-510, 2004
PubMed
22) Svartberg J, Agledahl I, Figenschau Y, et al : Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 20 : 378-387, 2008
PubMed
23) Behre HH, Kliesch S, Leifke E, et al : Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82 : 2386-2390, 1997
 
24) Kenny AM, Prestwood KM, Marcello KM, et al : Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 55 : M492-M497, 2000
 
25) Fink HA, Ewing SK, Ensrud KE, et al : Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91 : 3908-3915, 2006
 
26) Van den Beld AW, de Jong FH, Grobbee DE, et al : Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85 : 3276-3282, 2000
 
27) Michael H, Harkonen PL, Vaananen HK, et al : Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20 : 2224-2232, 2005
PubMed
28) Bassil N, Alkaade S, Morley J : The benefits and risks of testosterone replacement therapy : a review. Ther Clin Risk Manag 5 : 427-448, 2009
PubMed
29) Basurto L, Zarate A, Gomez R, et al : Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male 11 : 140-145, 2008
 
P.34 掲載の参考文献
1) World Health Organization : Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report Series 843, Geneva, 1994
 
2) 宗圓聰, 福永仁夫, 杉本利嗣, 他 : 原発性骨粗鬆症の診断基準 (2012年度改訂版). Osteoporosis Jpn 21 : 9-22, 2013
Medical*Online
3) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 285 : 785-795, 2001
PubMed
4) 折茂肇, 林泰史, 福永仁夫, 他 : 原発性骨粗鬆症の診断基準 (2000年度改訂版). 日骨代謝会誌 18 : 76-82, 2001
Medical*Online
5) Kanis JA, Johnell O, Oden A, et al : Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69 : 218-221, 2001
PubMed
6) de Laet CE, van der Klift M, Hofman A, et al : Osteoporosis in men and women : a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 17 : 2231-2236, 2002
 
7) Black DM, Cummings SR, Karpf DB, et al : Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 : 1535-1541, 1996
 
8) 森諭史, 宗圓聰, 萩野浩, 他 : 椎体骨折評価基準 (2012年度改訂版). Osteoporosis Jpn 21 : 25-32, 2013
Medical*Online
9) Genant HK, Wu CY, van Kuijk C, et al : Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8 : 1137-1148, 1993
PubMed
10) Schousboe JT, Vokes T, Broy SB, et al : Vertebral Fracture Assessment : the 2007 ISCD Official Positions. J Clin Densitom 11 : 92-108, 2008
PubMed
11) Ferrar L, Jiang G, Cawthon PM, et al ; Osteoporotic Fractures in Men (MrOS) Study : Identification of vertebral fracture and non-osteoporotic short vertebral height in men : the MrOS study. J Bone Miner Res 22 : 1434-1441, 2007
PubMed
12) Dominguez S, Liu P, Roberts C, et al : Prevalence of traumatic hip and pelvic fractures in patients with suspected hip fracture and negative initial standard radiographs--a study of emergency department patients. Acad Emerg Med 12 : 366-369, 2005
PubMed
13) Frihagen F, Nordsletten L, Tariq R, et al : MRI diagnosis of occult hip fractures. Acta Orthop 76 : 524-530, 2005
PubMed
14) Holder LE, Schwarz C, Wernicke PG, et al : Radionuclide bone imaging in the early detection of fractures of the proximal femur (hip) : multifactorial analysis. Radiology 174 : 509-515, 1990
PubMed
P.41 掲載の参考文献
1) NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285 : 785-795, 2001
PubMed
2) 日本骨代謝学会, 日本骨粗鬆症学会合同原発性骨粗鬆症診断基準改訂検討委員会編 : 原発性骨粗鬆症の診断基準 (2012年度改訂版). Osteoporosis Jpn 21 : 9-21, 2013
 
3) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2011年版. ライフサイエンス出版, 東京, 2011
 
4) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2015年版. ライフサイエンス出版, 東京, 2015
 
5) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2006年版. ライフサイエンス出版, 東京, 2006
 
6) Kanis JA, Oden A, Johnell O, et al : The use of clinical risk factors enhances the performance of BMD in the prediction of hip fracture and osteoporotic fractures in men and women. Osteoporos Int 18 : 1033-1046, 2007
PubMed
7) The World Health Organization Fracture Risk Assessment Tool. (http://www.shef.ac.uk/FRAX)
 
8) Fujiwara S, Nakamura T, Orimo H, et al : Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX-TM). Osteoporos Int DOI 10.1007/s00198-007-0544-4, 2008
 
9) Watts NB, Ettinger B, Leboff MS : Perspective FRAX Facts. J Bone Miner Res 24 : 975-979, 2009
 
10) Clinician's Guide to Prevention and treatment of Osteoporosis. National Osteoporosis Foundation, Washington, D.C., 2010
 
P.47 掲載の参考文献
1) 日本排尿機能学会夜間頻尿診療ガイドライン作成委員会 : 夜間頻尿診療ガイドライン. ブラックウェルパブリッシング, 2009
 
2) Homma Y, Yamaguchi O, Hayashi K ; Neurogenic Bladder Society Committee : Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 68 : 560-564, 2006
PubMed
3) 日本排尿機能学会過活動膀胱ガイドライン作成委員会 : 過活動膀胱診療ガイドライン改訂ダイジェスト版. ブラックウェルパブリッシング, 2008
 
4) 山本精三 : 認知症と整形外科的疾患. Clin Neuroscience 25 : 224-225, 2007
 
5) 平成7年度-平成8年度科学研究費補助金研究成果報告書 : 地域の高齢者における転倒・骨折に関する総合的研究 (代表 柴田博). p.163, 1997
 
6) Melton LJ III, Riggs BL : Epidemiology of age-related fractures. In Avioli LV ed. The Osteoporotic Syndrome, New York, Grune & Stratton, p.45-72, 1983
 
7) Nevitt MC, Cummings SR, Kidd S, et al : Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA 261 : 2663-2668, 1989
 
8) Parsons JK, Mougey J, Lambert L, et al : Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 104 : 63-68, 2009
PubMed
9) 新野直明, 中村健一 : 老人ホームにおける高齢者の転倒調査-転倒の発生状況と関連要因. 日老医誌 33 : 12-16, 1996
 
10) Stewart RB, Moore MT, May FE, et al : Nocturia : a risk factor for falls in the elderly. J Am Geriatr Soc 40 : 1217-1220, 1992
PubMed
11) Vaughan CP, Brown CJ, Goode PS, et al : The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract 64 : 577-583, 2010
 
12) Temml C, Ponholzer A, Gutjahr G, et al : Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 28 : 949-952, 2009
PubMed
13) Galizia G, Langellotto A, Cacciatore F, et al : Association between noctuira and fallsrelated long-term mortality risk in the elderly. J Am Med Dir Assoc 13 : 640-644, 2012
PubMed
14) Nakagawa H, Niu K, Hozawa A, et al : Impact of nocturia on bone fracture and mortality in older individuals : a Japanese longitudinal cohort study. J Urol 184 : 1413-1418, 2010
 
15) Hu TW, Wagner TH : Health-related consequences of overactive bladder : an economic perspective. BJU Int 96 : 43-45, 2005
PubMed
16) 赤倉功一郎 : 泌尿器の立場からみた高齢者の転倒予防. 転倒予防医学百科 (武藤芳照編), 日本医事新報社, p.144-147, 2008
 
17) 赤倉功一郎 : 高齢者の前立腺疾患と転倒・骨折予防-整形外科医に必要な実践知識-. MB Orthopaedics 22 : 68-72, 2009
 
18) Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan : 2000 report from the Japanese Urological Association. Int J Urol 12 : 46-61, 2005
PubMed
19) van den Beld AW, de Jong FH, Grobbee DE, et al : Measures of bioavailable serum testosterone and estradiol and their relationship with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 85 : 3267-3282, 2000
 
20) Orwoll E, Lambert LC, Marshall LM, et al : Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med 166 : 2124-2131, 2006
PubMed
21) Shahinian VB, Kuo YF, Freeman JL, et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 : 154-164, 2005
PubMed
22) Morgans AK, Fan KH, Koyama T, et al : Bone complications among prostate cancer survivors : long-term follow-up from the prostate cancer outcomes study. Prostate Cancer Prostatic Dis 17 : 338-342, 2014
PubMed
23) Oefelein MG, Ricchiuti V, Conrad W, et al : Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 : 1005-1007, 2002
PubMed
24) 鳥羽研二, 大河内二郎, 高橋泰, 他 : 転倒リスク予測のための「転倒スコア」の開発と妥当性の検証. 日老医誌 42 : 346-352, 2005
 
25) Rafiq M, McGovern A, Jones S, et al : Falls in the elderly were predicted opportunistically using a decision tree and systematically using a database-driven screening tool. J Clin Epidemiol 67 : 877-886, 2014
PubMed
26) Gillespie LD, Robertson MC, Gillespie WJ, et al : Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9 : CD007146, 2012
PubMed
27) 武藤芳照 : 転倒予防教室の設立と実践. 骨・関節・靭帯 19 : 17-25, 2006
Medical*Online
28) 安田彩 : 高齢者の転倒予防と住環境の整備. 転倒予防医学百科 (武藤芳照編), 日本医事新報社, p.226-229, 2008
 
29) Chapple CR, Kaplan SA, Mitcheson D, et al : Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β (3) -adrenoceptor agonist, in overactive bladder. Eur Urol 63 : 296-305, 2013
 
P.62 掲載の参考文献
1) 日本骨粗鬆症学会 骨粗鬆症の予防と治療ガイドライン作成委員会 (代表 折茂肇) : 骨粗鬆症の予防と治療のガイドライン 2011年版. ライフサイエンス出版社, 2011
 
2) 西澤良記, 三浦雅一, 稲葉雅章 : これだけは知っておきたい骨代謝マーカーの基礎と適正使用 骨代謝マーカー 改訂版, 医薬ジャーナル, 2010
 
3) 日本骨粗鬆症学会 骨代謝マーカー検討委員会 (代表 西澤良記) : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2012年版). Osteoporosis Jpn 20 : 33-53, 2012
 
4) Nishizawa Y, Ohta H, Miura M, et al : Guidelines for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 31 : 1-15, 2013
PubMed
5) Saito M, Marumo K : Collagen-crosslinks as a determinant of bone quality : possible explanation for bone fragility in aging, osteoporosis and diabetes mellitus. Osteoporosis Int 21 : 195-214, 2010
PubMed
6) Shiraki M, Urano T, Kuroda T, et al : The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab 26 : 595-602, 2008
PubMed
7) Bjarnason NH, Henriksen EE, Alexandersen P, et al : Mechanism of circadian variation in bone resorption. Bone 30 : 307-313, 2002
PubMed
8) Inaba M, Kurajoh M, Okuno S, et al : Poor muscle quality rather than reduced lean body mass is responsible for the lower serum creatinine level in hemodialysis patients with diabetes mellitus. Clin Nephrol 74 : 266-272, 2010
PubMed
9) Yamada S, Inaba M, Kurajoh M, et al : Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease : independence from renal dysfunction. Clin Endocrinol (Oxf) 69 : 189-196, 2008
PubMed
10) Delmas PD, Eastell R, Garnero P, et al : The Use of Biochemical Markers of Bone Turnover in Osteoporosis. Osteoporosis Int 11 (Suppl. 6) : S2-17, 2000
 
11) Miyauchi A, Matsumoto T, Sugimoto T, et al : Effects of teriparatide on bone mineral density and bone turnover markersin Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study : 12-Months, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47 : 493-502, 2010
 
12) Watts NB, Adler RA, Bilezikian JP, et al : Osteoporosis in men : an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97 : 1802-1822, 2012
PubMed
13) Eastell R, Garnero P, Audebert C, et al : Reference intervals of bone turnover markers in healthy premenopausal women : results from a cross-sectional European study. Bone 50 : 1141-1147, 2012
PubMed
14) Vasikaran S, Eastell R, Bruyere O, et al : Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment : a need for international reference standards. Osteoporos Int 22 : 391-420, 2011
PubMed
15) Johoon L, Vasikaran S : Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis. Ann Lab Med 32 : 105-112, 2012
 
16) Bauer D, Krege J, Lane N, et al : National Bone Health Alliance Bone Turnover Marker Project : current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 23 : 2425-2433, 2012
PubMed
17) リチャード イーステル, 三浦雅一 : 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドラインの役割と日本および欧米における標準化・ハーモナイゼーションについて. 医学と薬学 70 : 753-767, 2013
 
P.67 掲載の参考文献
1) Lacey DL, Timms E, Tan HL, et al : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 : 165-176, 1998
PubMed
2) McClung MR, Lewiecki EM, Cohen SB, et al : Denosmab in postmenopausal women with low bone mineral density. N Engl J Med 354 : 821-831, 2006
 
3) Nakamura T, Matsumoto T, Sugimoto T, et al : Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23 : 1131-1140, 2012
 
4) Ellis GK, Bone HG, Chlebowski R, et al : Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 : 4875-4882, 2008
PubMed
5) Cummings SR, San Martin J, McClung MR, et al : Denosumab for prevention of fracture in postmenopausal women with osteoporosis. N Engl J Med 361 : 756-765, 2009
PubMed
6) Nakamura T, Matsumoto T, Sugimoto T, et al : Clinical Trials Express : fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis : denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99 : 2599-2607, 2014
PubMed
7) Smith MR, Egerdie B, Toriz NH, et al : Denosumab in men receiving androgendeprivation therapy for prostate cancer. N Engl J Med 361 : 754-755, 2009
 
8) Egerdie RB, Smith MR, Tammela TL, et al : Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prestatic Dis 15 : 308-312, 2012
 
9) Smith MR, Saad F, Coleman R, et al : Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randamised, placebe-controlled trial. Lancet 379 : 39-46, 2012
 
10) Lipton A, Fizazi K, Stopeck AT, et al : Superiority of denosumab to zoledronic acid for prevention of skeletal-related events ; a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48 : 3082-3092, 2012
PubMed
11) Snedecor SJ, Carter JA, Kaura S, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostatic cancer : A cost-effictiveness analysis. J Med Econ 16 : 19-29, 2013
 
P.75 掲載の参考文献
1) Neer RM, Arnaud CD, Zanchetta JR, et al : Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 : 1434-1441, 2001
PubMed
2) Brunkow ME, Gardner JC, Van Ness J, et al : Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68 : 577-589, 2001
PubMed
3) Balemans W, Ebeling M, Patel N, et al : Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10 : 537-543, 2001
 
4) Little RD, Carulli JP, Del Mastro RG, et al : A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 : 11-19, 2002
PubMed
5) Boyden LM, Mao J, Belsky J, et al : High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 : 1513-1521, 2002
PubMed
6) Keller H, Kneissel M : SOST is a target gene for PTH in bone. Bone 37 : 148-158, 2005
PubMed
7) Bilezikian JP : Combination anabolic and antiresorptive therapy for osteoporosis : opening the anabolic window. Curr Osteoporos Rep 6 : 24-30, 2008
PubMed
8) Kurland ES, Cosman F, McMahon DJ, et al : Parathyroid hormone as a therapy for idiopathic osteoporosis in men : Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85 : 3069-3076, 2000
 
9) Orwoll ES, Scheele WH, Paul S, et al : The effect of teriparatide [human parathyroid hormone (1-34) ] therapy on bone density in men with osteoporosis. J Bone Miner Res 18 : 9-17, 2003
 
10) Kaufman JM, Orwoll E, Goemaere S, et al : Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis : treatment and discontinuation of therapy. Osteoporos Int 16 : 510-516, 2005
PubMed
11) Niimi R, Kono T, Nishihara A, et al : Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int 26 : 1303-1309, 2015
PubMed
12) Saag KG, Shane E, Boonen S, et al : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357 : 2028-2039, 2007
PubMed
13) Langdahl BL, Marin F, Shane E, et al : Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis : an analysis by gender and menopausal status. Osteoporos Int 20 : 2095-2104, 2009
PubMed
14) Saag KG, Zanchetta JR, Devogelaer JP, et al : Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis : thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60 : 3346-3355, 2009
PubMed
15) Gluer CC, Marin F, Ringe JD, et al : Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men : 18-month results of the EuroGIOPs trial. J Bone Miner Res 28 : 1355-1368, 2013
 
16) Finkelstein JS, Hayes A, Hunzelman JL, et al : The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349 : 1216-1226, 2003
PubMed
17) Walker MD, Cusano NE, Sliney J Jr, et al : Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44 : 237-246, 2013
PubMed
18) Cosman F, Eriksen EF, Recknor C, et al : Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34) ] in postmenopausal osteoporosis. J Bone Miner Res 26 : 503-511, 2011
PubMed
19) Kurland ES, Heller SL, Diamond B, et al : The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34) ]. Osteoporos Int 15 : 992-997, 2004
PubMed
20) Finkelstein JS, Wyland JJ, Leder BZ, et al : Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94 : 2495-2501, 2009
PubMed
21) Vahle JL, Sato M, Long GG, et al : Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30 : 312-321, 2002
PubMed
22) Harvey NC, Kanis JA, Oden A, et al : Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int in press
PubMed
P.83 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2011年版. ライフサイエンス出版社, 東京, 2011
 
2) Iwamoto J, Sato Y, Takeda T, et al : High-dose vitamin K supplementation reduces fracture incidence in postmenopausal women : a review of the literature. Nutr Res 29 : 221-228, 2009
PubMed
3) Shearer MJ : Vitamin K. Lancet 345 : 229-234, 1995
PubMed
4) 白木正孝, 青木長寿, 山崎典美, 他 : 電気化学発光免疫法による血清中低カルボキシル化オステオカルシン (ucOC) 測定キットの臨床的有用性の検討-カットオフ値の設定と骨粗鬆症患者におけるビタミンK2剤選択時の有用性の検討-. 医学と薬学 57 : 537-546, 2007
Medical*Online
5) Okano T, Shimomura Y, Yamane M, et al : Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice : two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem 283 : 11270-11279, 2008
PubMed
6) Suhara Y, Wada A, Okano T, et al : Elucidation of the mechanism producing menaquinone-4 in osteoblastic cells. Bioorg Med Chem Lett 19 : 1054-1057, 2009
 
7) Nakagawa K, Hirota Y, Sawada N, et al : Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 468 : 117-121, 2010
PubMed
8) Booth SL, Broe KE, Peterson JW, et al : Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab 89 : 4904-4909, 2004
PubMed
9) McLean RR, Booth SL, Kiel DP, et al : Association of dietary and biochemical measures of vitamin K with quantitative ultrasound of the heel in men and women. Osteoporos Int 17 : 600-607, 2006
PubMed
10) Fujita Y, Iki M, Tamaki J, et al : Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men : the Fujiwarakyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int 23 : 705-714, 2012
PubMed
11) Yaegashi Y, Onoda T, Tanno K, et al : Association of hip fracture incidence and intake of calcium, magnesium, vitamin D, and vitamin K. Eur J Epidemiol 23 : 219-225, 2008
PubMed
12) Shiraki M, Itabashi A : Short-term menatetrenone therapy increases gammacarboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis : a randomized prospective study. J Bone Miner Metab 27 : 333-340, 2009
PubMed
13) Purwosunu Y, Muharram, Rachman IA, et al : Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet-Gynaecol Res 32 : 230-234, 2006
PubMed
14) Shiraki M, Shiraki Y, Aoki C, et al : Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15 : 515-521, 2000
 
15) 折茂肇, 藤田拓男, 小野村敏信, 他 : 骨粗鬆症に対するEa-0167 (Menatetrenone) の臨床評価-アルファカルシドールを対照とした臨床第III相多施設二重盲検比較試験-. 臨床評価 20 : 45-100, 1992
 
16) Ushiroyama T, Ikeda A, Ueki M, et al : Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41 : 211-221, 2002
 
17) Booth SL, Dallel G, Shea MK, et al : Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 3 : 1217-1223, 2008
 
18) Forli L, Bollerslev J, Simonsen S, et al : Dietary vitamin K2 supplement improves bone status after lung and heart transplantation. Transplantation 89 : 458-464, 2010
PubMed
19) Sato Y, Honda Y, Oizumi K, et al : Menatetrenone ameliorates osteopenia in disuseaffected limbs of vitamin D- and K-deficient stroke patients. Bone 23 : 291-296, 1998
 
20) Sasaki N, Kusano E, Takahashi H, et al : Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23 : 41-47, 2005
PubMed
21) Iwamoto J, Takeda T, Yeh JK, et al : Effect of vitamin K2 on cortical and cancellous bones in orchidectomized young rats. Maturitas 44 : 19-27, 2003
 
22) Iwamoto J, Yeh JK, Takeda T, et al : Effect of vitamin K2 on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res 18 : 776-783, 2003
 
23) Bilezikian JP : Osteoporosis in men. J Clin Endocrinol Metab 84 : 3431-3434, 1999
 
24) Brown JE, Neville-Webbe H, Coleman RE : The role of bisphosphonates in breast and prostate cancers. Endocr Related Cancer 11 : 207-224, 2004
PubMed
25) Nimptsch K, Rohrmann S, Kaaks R, et al : Dietary vitamin K intake in relation to cancer incidence and mortality : result from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am J Clin Nutr 91 : 1348-1358, 2010
PubMed
P.94 掲載の参考文献
1) Tanaka H, Seino Y : Direct action of 1, 25-dihydroxyvitamin D on bone : VDRKO bone shows excessive bone formation in normal mineral condition. J Steroid Biochem Mol Biol 89-90 (1-5) : 343-345, 2004
 
2) Shiraishi A, Takeda S, Masaki T, et al : Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis : distinct actions from estrogen. J Bone Miner Res 15 : 770-779, 2000
 
3) Matsumoto T, Ito M, Hayashi Y, et al : A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. Bone 49 : 605-612, 2011
PubMed
4) Avenell A, Gillespie WJ, Gillespie LD, et al : Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No. : CD000227. DOI : 10. 1002/14651858. CD000227. pub3
 
5) Papadimitropoulos E, Wells G, Shea B, et al ; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group : Meta-analyses of therapies for postmenopausal osteoporosis. VIII : Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23 : 560-569, 2002
PubMed
6) Orimo H, Nakamura T, Fukunaga M, et al ; A-TOP (Adequate Treatment of Osteoporosis) research group : Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture : the Japanese Osteoporosis Intervention Trial (JOINT) -02. Curr Med Res Opin 27 : 1273-1284, 2011
 
7) Kubodera N, Tsuji N, Uchiyama Y, et al : A new active vitamin D analog, ED-71, causes increase in bone mass with preferential effects on bone in osteoporotic patients. J Cell Biochem 88 : 286-289, 2003
 
8) Uchiyama Y, HiguchI Y, Takeda S, et al : ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30 : 582-588, 2002
 
9) Matsumoto T, Miki T, Hagino H, et al : A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation : a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90 : 5031-5036, 2005
PubMed
10) Sakai A, Ito M, Tomomitsu T, et al : Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int 26 : 1193-1202, 2015. doi : 0.1007/s00198-014-2991-z
 
P.97 掲載の参考文献
1) Steck SE, Arab L, Zhang H, et al : Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. PLoS One 10 : e0125151, 2015
PubMed
2) Wieczorek K, Braczkowski RS, Skrzypek M, et al : The comparison between vitamin d concentration in upper silesia patients with prostate cancer and with benign prostatic hyperplasia. J Biol Regul Homeost Agents 29 : 207-211, 2015
PubMed
3) Murphy AB, Nyame Y, Martin IK, et al : Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res 20 : 2289-2299, 2014
PubMed
4) Grant WB : Vitamin D status : ready for guiding prostate cancer diagnosis and treatment? Clin Cancer Res 20 : 2241-2243, 2014
PubMed
5) Marshall DT, Savage SJ, Garrett-Mayer E, et al : Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 97 : 2315-2324, 2012
 
6) Wagner D, Trudel D, Van der Kwast T, et al : Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 98 : 1498-1507, 2013
PubMed
7) Trummer O, Langsenlehner U, Krenn-Pilko S, et al : Vitamin D and prostate cancer prognosis : a Mendelian randomization study. World J Urol 2015
 
8) Der T, Bailey BA, Youssef D, et al : Vitamin D and prostate cancer survival in veterans. Mil Med 179 : 81-84, 2014
PubMed
9) Schwartz GG : Vitamin D in blood and risk of prostate cancer : lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 23 : 1447-1449, 2014
PubMed
10) Jingwi EY, Abbas M, Ricks-Santi L, et al : Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res 35 : 1549-1558, 2015
PubMed
11) Shui IM, Mondul AM, Lindstrom S, et al : Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer 121 : 1949-1956, 2015
PubMed
12) Gilbert R, Bonilla C, Metcalfe C, et al : Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer : a nested case-control study. Cancer Causes Control 26 : 205-218, 2015
PubMed
13) Giangreco AA, Dambal S, Wagner D, et al : Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model. J Steroid Biochem Mol Biol 148 : 156-165, 2015
 
14) Datta M, Schwartz GG : Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer : a critical review. Oncologist 17 : 1171-1179, 2012
PubMed
15) Alibhai SM, Mohamedali HZ, Gulamhusein H, et al : Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporos Int 24 : 2571-2579, 2013
PubMed
P.108 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2015年版. ライフサイエンス出版, 東京, 2015
 
2) 須田立雄 : 血清カルシウムの恒常性とその調節機構, in 新骨の科学. 須田立雄編, 医歯薬出版, 東京, p.193-218, 2007
 
3) 吉村健史, 伊藤彰敏 : カルシトニン. 日薬理誌 135 : 40-41, 2010
Medical*Online
4) Ishida Y, Kawai S : Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis : The Yamaguchi Osteoporosis Prevention Study. Am J Med 117 : 549-555, 2004
PubMed
5) 藤田拓男, 井上哲郎, 折茂肇, 他 : 骨粗鬆症に対するエルカトニンの効果 プラセボを対照薬とした多施設二重盲検比較試験. 医学のあゆみ 152 : 261-282, 1990
Medical*Online
6) Orimo H, Morii H, Inoue T, et al : Effect of elcatonin on involutional osteoporosis. J Bone Miner Metab 14 : 73-78, 1996
 
7) Meschia M, Brincat M, Barbacini P, et al : A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 53 : 17-20, 1993
PubMed
8) Fujita T, Fuji Y, Goto B, et al : A three-year comparative trial in osteoporosis treatment : Effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15 : 223-226, 1997
 
9) Ushiroyama T, Ikeda A, Sakai M, et al : Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis : a prospective study of long-term and continuous administration with low dose calcitonin. Maturitas 40 : 229-238, 2001
PubMed
10) Rico H, Revilla M, Hernandez ER, et al : Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin : a prospective study. Calcif Tissue Int 56 : 181-185, 1995
PubMed
11) Rico H, Hernandez ER, Revilla M, et al : Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16 : 131-138, 1992
PubMed
12) Chesnut CH, 3rd, Silverman S, Andriano K, et al : A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis : the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109 : 267-276, 2000
 
13) Kanis JA, Johnell O, Gullberg B, et al : Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 305 (6862) : 1124-1128, 1992
PubMed
14) Forman LJ, Tingle V, Estilow S, et al. The response to analgesia testing is affected by gonadal steroids in the rat. Life Sci 45 : 447-454, 1989
PubMed
15) 射場浩介, 山下敏彦 : 骨粗鬆症による疼痛疼痛対策と管理. Orthopaedics 25 : 117-122, 2012
 
16) Appelboom T : Calcitonin in reflex sympathetic dystrophy syndrome and other painful conditions. Bone 30 (5 Suppl) : 84S-86S, 2002
 
17) 伊丹康人, 井上哲郎, 高橋栄明, 他 : 老人性骨粗鬆症に伴う腰背痛に対するエルカトニンの効果 ; 多施設二重盲検法による 4 : 1 用量比の群間比較. 医学のあゆみ 120 : 1180-1195, 1982
 
18) 中野哲雄 : 骨粗鬆症性椎体圧迫骨折による急性疼痛に対するカルシトニン製剤 (エルカトニン) の効果 セミブラインド化無作為化比較試験による検討. Osteoporosis Jpn 19 : 151-156, 2011
 
19) 中村正生, 清水克時 : 腰下肢痛を伴う骨粗鬆症症例に対する日本語版Roland-Morris Disability Questionnaireを用いたQOL評価エルカトニン製剤投与下での疼痛に関連するQOL改善についての検討. Osteoporosis Jpn 16 : 333-341, 2008
 
20) Knopp JA, Diner BM, Blitz M, et al : Calcitonin for treating acute pain of osteoporotic vertebral compression fractures : a systematic review of randomized, controlled trials. Osteoporos Int 16 : 1281-1290, 2005
PubMed
21) Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al : Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures : a systematic review and meta-analysis. Osteoporos Int 23 : 17-38, 2012
PubMed
22) Yoh K, Tanaka K, Ishikawa A, et al : Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23 : 167-173, 2005
PubMed
23) Peichl P, Marteau R, Griesmacher A, et al : Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. J Bone Miner Metab 23 : 243-252, 2005
PubMed
24) 萩野浩, 岡野徹, 楠城誉朗, 他 : 大腿骨近位部骨折症例の術後評価におけるカルシトニン製剤の効果-ADL, QOL改善効果に関する検討. Osteoporosis Jpn 22 : 379-386, 2014
Medical*Online
25) 中野哲雄, 越智龍弥, 稲葉大輔, 他 : 大腿骨頸部・転子部骨折症例に対するエルカトニン投与が術後リハビリテーションに及ぼす影響の検討 ランダム化比較試験. Osteoporosis Jpn 17 : 692-696, 2009
Medical*Online
26) 小林真司, 小林なぎさ : 骨粗鬆症を有する女性の大腿骨近位部骨折に対するカルシトニン製剤の鎮痛効果. 日ペインクリニック会誌 20 : 79-82, 2013
Medical*Online
27) Sun LM, Lin MC, Muo CH, et al : Calcitonin nasal spray and increased cancer risk : a population-based nested case-control study. J Clin Endocrinol Metab 99 : 4259-4264, 2014
 
P.116 掲載の参考文献
1) Saad F, Adachi JD, Brown JP, et al : Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26 : 5465-5476, 2008
PubMed
2) Fleisch H : Bisphosphonates in bone disease. From the laboratory to the patient, 3rd ed. New York : The Parthenon Publishing Group Inc., 1997
 
3) Luckman SP, Hughes DE, Coxon FP, et al : Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13 : 581-589, 1998
 
4) Orwoll E, Ettinger M, Weiss S, et al : Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 : 604-610, 2000
 
5) Ringe JD, Dorst A, Faber H, et al : Alendronate treatment of established primary osteoporosis in men : 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 24 : 110-113, 2004
PubMed
6) Sawka AM, Papaioannou A, Adachi JD, et al : Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of antifracture efficacy in women. BMC Musculoskeletal Disord 6 : 39, 2005
 
7) Boonen S, Orwoll ES, Wenderoth D, et al : Once-weekly risedronate in men with osteoporosis : results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24 : 719-725, 2009
PubMed
8) Boonen S, Lorenc RS, Wenderoth D, et al : Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment : Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone 51 : 383-388, 2012
PubMed
9) Ringe JD, Farahmand P, Faber H, et al : Sustained efficacy of risedronate in men with primary and secondary osteoporosis : results of a 2-year study. Rheumatol Int 29 : 311-315, 2009
PubMed
10) Orwoll ES, Binkley NC, Lewiecki EM, et al : Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46 : 970-976, 2010
PubMed
11) Boonen S, Orwoll E, Magaziner J, et al : Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc 59 : 2084-2090, 2011
PubMed
12) Boonen S, Reginster JY, Kaufman JM, et al : Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 367 : 1714-1723, 2012
PubMed
13) Orwoll ES, Miller PD, Adachi JD, et al : Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis : a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25 : 2239-2250, 2010
 
14) Taylor LG, Canfield SE, Du XL : Review of major adverse effects of androgendeprivation therapy in men with prostate cancer. Cancer 115 : 2388-2399, 2009
PubMed
15) Shahinian VB, Kuo YF, Freeman JL, et al : Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 : 154-164, 2005
PubMed
16) Krupski TL, Smith MR, Lee WC, et al : Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 101 : 541-549, 2004
PubMed
17) Smith MR, Boyce SP, Moyneur E, et al : Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175 : 136-139, 2006 ; discussion 9.
 
18) Smith MR, Lee WC, Brandman J, et al : Gonadotropin-releasing hormone agonists and fracture risk : a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 : 7897-7903, 2005
 
19) Greenspan SL, Nelson JB, Trump DL, et al : Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : a randomized trial. Ann Intern Med 146 : 416-424, 2007
 
20) Greenspan SL, Nelson JB, Trump DL, et al : Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 26 : 4426-4434, 2008
PubMed
21) Klotz LH, McNeill IY, Kebabdjian M, et al : A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer : The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study. Eur Urol 63 : 927-935, 2013
PubMed
22) Izumi K, Mizokami A, Sugimoto K, et al : Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73 : 1342-1346, 2009
PubMed
23) Choo R, Lukka H, Cheung P, et al : Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys 85 : 1239-1245, 2013
PubMed
24) Smith MR, McGovern FJ, Zietman AL, et al : Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 : 948-955, 2001
PubMed
25) Smith MR, Eastham J, Gleason DM, et al : Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 : 2008-2012, 2003
PubMed
26) Michaelson MD, Kaufman DS, Lee H, et al : Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 : 1038-1042, 2007
PubMed
27) Satoh T, Kimura M, Matsumoto K, et al : Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormonenaive prostate carcinoma. Cancer 115 : 3468-3474, 2009
PubMed
28) Kachnic LA, Pugh SL, Tai P, et al : RTOG 0518 : randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis 16 : 382-386, 2013
PubMed
29) Serpa Neto A, Tobias-Machado M, Esteves MA, et al : Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer : a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 15 : 36-44, 2012
PubMed
30) Hillner BE, Ingle JN, Chlebowski RT, et al : American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 : 4042-4057, 2003
 
31) Hadji P, Body JJ, Aapro MS, et al : Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19 : 1407-1416, 2008
 
32) Coleman R, Body JJ, Aapro M, et al ; ESMO Guidelines Working Group : Bone health in cancer patients : ESMO Clinical Practice Guidelines. Ann Oncol 25 (Suppl. 3) : iii124-137, 2014
 

II. ステロイド性骨粗鬆症の特徴と管理

P.122 掲載の参考文献
1) Adler RA : Osteoporosis in men : insights for the clinician. Ther Adv Musculoskelet Dis 3 : 191-200, 2011
PubMed
2) Keith BD : Systematic review of the clinical effect of glucocorticoids on onhematologic malignancy. BMC Cancer 8 : 84, 2008
PubMed
3) Heng DY, Chi KN : Prednine monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 13 : 3335-3339, 2006
 
4) Fossa SD, Jacobsen AB, Ginman C, et al : Weekly docetaxel and predonisolone versus prednisolone alone in androgen-independent prostate cancer : a randomized phase II study. Eur Urol 52 : 1691-1698, 2007
 
5) Collins R, Fenwick E, Trowman R, et al : A systematic review and economic model of the clinical effectiveness and costeffectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess 11 : 1-179, 2007
PubMed
6) Akakura K, Suzuki H, Ueda T, et al : Possible mechanism of dexamethasone therapy for prostate cancer : suppression of circulating level of interleukin-6. Prostate 56 : 106-109, 2003
PubMed
7) van Staa TP, Leufkens HG, Abenhaim L, et al : Oral corticosteroids and fracture risk : relationship to daily and cumulative doses. Rheumatology (Oxford) 39 : 1383-1389, 2000
PubMed
8) van Staa TP, Leufkens HG, Cooper C : The epidemiology of corticosteroid-induced osteoporosis : meta-analysis. Osteoporos Int 13 : 777-787, 2002
PubMed
9) Suzuki Y, Nawata H, Soen S, et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014
PubMed
10) Lane NE, Lukert B : The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27 : 465-483, 1998
PubMed
11) 原発性骨粗鬆症診断基準改訂検討委員会編 : 原発性骨粗鬆症の診断基準 (2012年度改訂版). Osteoporosis Jpn 21 : 9-21, 2013
 
12) Grossman JM, Gordon R, Ranganath VK, et al : American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoide-induced osteoporosis. Arthritis Care Res 62 : 1515-1526, 2010
 
13) Saag KG, Emkey R, Schnitzer TJ, et al : Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339 : 292-299, 1998
 
14) Adachi JD, Saag KG, Delmas PD, et al : Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids : a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 : 201-211, 2001
 
15) Saag KG, Zanchetta JR, Devogelaer JP, et al : Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis : thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60 : 3346-3355, 2009
PubMed
16) Saag KG, Shane E, Boonen S, et al : Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357 : 2028-2039, 2007
PubMed

III. 前立腺癌骨管理アルゴリズム - レベル 1 エビデンスに準拠した薬剤選択の提言 -

P.134 掲載の参考文献
1) Van Hemelrijck M, Garmo H, Michaelsson K, et al : Mortality following Hip Fracture in Men with Prostate Cancer. PLoS One 8 : e74492, 2013
PubMed
2) Osteoporosis inmen [http://www.iofbonehealth.org]
 
3) FRAXR WHO Fracture Risk Assessment Tool [http://www.shef.ac.uk]
 
4) Pearson D, Horton B, Green DJ, et al : Vertebral morphometry by DXA : a comparison of supine lateral and decubitus lateral densitometers. J Clin Densitom 9 : 295-301, 2006
PubMed
5) NOF : The Man's Guide to Osteoporosis. In. : National Osteoporosis Foundation ; 2011
 
6) Orwoll E, Ettinger M, Weiss S, et al : Alendronate for the treatment of osteoporosis in men. N Engl J Med 343 : 604-610, 2000
 
7) Ringe JD, Faber H, Farahmand P, et al : Efficacy of risedronate in men with primary and secondary osteoporosis : results of a 1-year study. Rheumatol Int 26 : 427-431, 2006
PubMed
8) Lyles KW, Colon-Emeric CS, Magaziner JS, et al : Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 357 : nihpa40967, 2007
 
9) Kaufman JM, Orwoll E, Goemaere S, et al : Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis : treatment and discontinuation of therapy. Osteoporos Int 16 : 510-516, 2005
PubMed
10) Smith MR, Egerdie B, Hernandez Toriz N, et al : Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361 : 745-755, 2009
PubMed
11) Smith MR, Morton RA, Barnette KG, et al : Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 189 (1 Suppl) : S45-50, 2013
 
12) Smith MR, Halabi S, Ryan CJ, et al : Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases : results of CALGB 90202 (alliance). J Clin Oncol 32 : 1143-1150, 2014
 
13) Saad F, Gleason DM, Murray R, et al : A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002
 
14) Fizazi K, Carducci M, Smith M, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
15) Parker C, Nilsson S, Heinrich D, et al : Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 : 213-223, 2013
PubMed

IV. 骨転移病変の病態と診断

P.154 掲載の参考文献
1) Abrams HL, Spiro R, Goldstein N : Metastases in carcinoma : analysis of 1000 autopsied cases. Cancer 3 : 74-85, 1950
PubMed
2) Koutsilieris M : Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13 : 443-449, 1993
PubMed
3) Ramaswamy S, Ross KN, Lander ES, et al : A molecular signature of metastasis in primary solid tumors. Nat Genet 33 : 49-54, 2003
PubMed
4) Hauschka PV, Mavrakos AE, Iafrati MD, et al : Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261 : 12665-12674, 1986
PubMed
5) Kaplan RN, Riba RD, Zacharoulis S, et al : VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438 : 820-827, 2005
PubMed
6) Shiozawa Y, Havens AM, Pienta KJ, et al : The bone marrow niche : habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22 : 941-950, 2008
PubMed
7) Finak G, Bertos N, Pepin F, et al : Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14 : 518-527, 2008
PubMed
8) Hu M, Yao J, Carroll DK, et al : Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13 : 394-406, 2008
 
9) Arai F, Suda T : Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann N Y Acad Sci 1106 : 41-53, 2007
PubMed
10) Pecherstorfer M, Zimmer-Roth I, Schilling T, et al : The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80 : 97-103, 1995
PubMed
11) Garnero P, Buchs N, Zekri J, et al : Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 : 858-864, 2000
PubMed
12) Saad F, Gleason DM, Murray R, et al : A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002
 
13) Heidenreich A : Bisphosphonates in the management of metastatic prostate cancer. Oncology 65 (Suppl. 1) : 5-11, 2003
 
14) Yonou H, Kanomata N, Goya M, et al : Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 63 : 2096-2102, 2003
PubMed
15) Suda T, Takahashi N, Udagawa N, et al : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 : 345-357, 1999
PubMed
16) Roodman GD : Mechanisms of bone metastasis. N Engl J Med 350 : 1655-1664, 2004
PubMed
17) Blair JM, Zhou H, Seibel MJ, et al : Mechanisms of disease : roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3 : 41-49, 2006
PubMed
18) Jones DH, Nakashima T, Sanchez OH, et al : Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440 : 692-696, 2006
PubMed
19) Brown JM, Corey E, Lee ZD, et al : Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57 : 611-616, 2001
PubMed
20) Murakami T, Yamamoto M, Ono K, et al : Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252 : 747-752, 1998
PubMed
21) Takai H, Kanematsu M, Yano K, et al : Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273 : 27091-27096, 1998
PubMed
22) Odero-Marah VA, Wang R, Chu G, et al : Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18 : 858-870, 2008
PubMed
23) Kostenuik PJ, Sanchez-Sweatman O, Orr FW, et al : Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 14 : 19-26, 1996
 
24) Jacob K, Webber M, Benayahu D, et al : Osteonectin promotes prostate cancer cell migration and invasion : a possible mechanism for metastasis to bone. Cancer Res 59 : 4453-4457, 1999
PubMed
25) Iwamura M, di Sant'Agnese PA, Wu G, et al : Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 53 : 1724-1726, 1993
PubMed
26) Cramer SD, Peehl DM, Edgar MG, et al : Parathyroid hormone-related protein (PTH-rP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate 29 : 20-29, 1996
 
27) Peehl DM, Edgar MG, Cramer SD, et al : Parathyroid hormone-related protein is not an autocrine growth factor for normal prostate epithelial cells. Prostate 31 : 47-52, 1997
PubMed
28) Iwamura M, Abrahamson P, Schoen S, et al : Parathyroid hormone-related protein : A potential autocrine growth regulator in human prostate cancer cell lines. Urology 43 : 675-679, 1994
 
29) Stewart AF : PTH-rP (1-36) as a skeletal anabolic agent for the treatment of osteoporosis. Bone 19 : 303-306, 1996
 
30) Ono K, Akatsu T, Murakami T, et al : Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17 : 774-781, 2002
PubMed
31) Yoneda T, Sasaki A, Dunstan C, et al : Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99 : 2509-2517, 1997
PubMed
32) Goltzman D : Mechanisms of the development of osteoblastic metastases. Cancer 80 (8 Suppl) : 1581-1587, 1997
 
33) Peehl DM, Cohen P, Rosenfeld RG : The insulin-like growth factor system in the prostate. World J Urol 13 : 306-311, 1995
PubMed
34) Cohen P, Peehl DM, Graves HC, et al : Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142 : 407-415, 1994
PubMed
35) Maeda H, Yonou H, Yano K, et al : Prostatespecific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5. Biochem Biophys Res Commun 381 : 311-316, 2009
PubMed
36) Goya M, Miyamoto S, Nagai K, et al : Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulinlike growth factors. Cancer Res 64 : 6252-6258, 2004
PubMed
37) Morton DM and Barrack ER : Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55 : 2596-2602, 1995
PubMed
38) Shariat SF, Shalev M, Menesses-Diaz A, et al : Preoperative plasma levels of transforming growth factor beta (1) (TGF-beta (1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19 : 2856-2864, 2001
 
39) Guise TA, Mundy GR : Cancer and bone. Endocr Rev 19 : 18-54, 1998
 
40) Harris SE, Harris MA, Mahy P, et al : Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24 : 204-211, 1994
PubMed
41) Bentley H, Hamdy FC, Hart KA, et al : Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 66 : 1159-1163, 1992
PubMed
42) George D : Platelet-derived growth factor receptors : a therapeutic target in solid tumors. Semin Oncol 28 (5 Suppl. 17) : 27-33, 2001
 
43) Chott A, Sun Z, Morganstern D, et al : Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulinlike growth factor receptor. Am J Pathol 155 : 1271-1279, 1999
PubMed
44) Uehara H, Kim SJ, Karashima T, et al : Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95 : 458-470, 2003
 
45) Nelson JB, Hedican SP, George DJ, et al : Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1 : 944-949, 1995
PubMed
46) Granchi S, Brocchi S, Bonaccorsi L, et al : Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 49 : 267-277, 2001
PubMed
47) Tian E, Zhan F, Walker R, et al : The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 : 2483-2494, 2007
 
48) Hall CL, Kang S, MacDougald OA, et al : Role of Wnts in prostate cancer bone metastases. J Cell Biochem 7 : 661-672, 2006
 
49) Kuriyama M, Wang MC, Lee CI, et al : Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41 : 3874-3876, 1981
PubMed
50) Killian CS, Corral DA, Kawinski E, et al : Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192 : 940-947, 1993
 
51) Oesterling JE : Using PSA to eliminate the staging radionuclide bone scan. Urol Clin North Am 20 : 705-711, 1993
PubMed
52) Doherty A, Smith G, Banks L, et al : Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer : implications for paracrine growth. J Pathol 188 : 278-281, 1999
PubMed
53) Yonou H, Aoyagi Y, Kanomata N, et al : Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun 289 : 1082-1087, 2001
PubMed
54) Goya M, Ishii G, Miyamoto S, et al : Prostate-specific antigen induces apoptosis of osteoclast precursors : potential role in osteoblastic bone metastases of prostate cancer. Prostate 66 : 1573-1584, 2006
PubMed
55) Lipton A, Costa L, Ali S, et al : Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28 (Suppl. 11) : 54-59, 2001
 
56) Coleman RE, Major P, Lipton A, et al : Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 : 4925-4935, 2005
PubMed
57) Yonou H, Yokose T, Kamijo T, et al : Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61 : 2177-2182, 2001
PubMed
58) Yonou H, Ochiai A, Goya M, et al : Intraosseous growth of human prostate cancer in implanted adult human bone : relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 58 : 406-413, 2004
PubMed
59) Zhang J, Dai J, Qi Y, et al : Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107 : 1235-1244, 2001
 
60) Yonou H, Ochiai A, Ashimine S, et al : The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Prostate 67 : 999-1009, 2007
PubMed
61) Capparelli C, Kostenuik PJ, Morony S, et al : Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60 : 783-787, 2000
 
62) Van Poznak CH, Temin S, Yee GC, et al : American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bonemodifying agents in metastatic breast cancer. J Clin Oncol 29 : 1221-1227, 2011
 
63) Kearns AE, Khosla S, Kostenuik PJ : Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29 : 155-192, 2008
PubMed
64) Kostenuik PJ, Nguyen HQ, McCabe J, et al : Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knockin mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24 : 182-195, 2009
 
65) Fizazi K, Lipton A, Mariette X, et al : Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27 : 1564-1571, 2009
PubMed
66) Fizazi K, Carducci M, Smith M, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
67) Lipton A, Fizazi K, Stopeck AT, et al : Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48 : 3082-3092, 2012
PubMed
P.172 掲載の参考文献
1) Dennis ER, Jia X, Mezheritskiy IS, et al : Bone scan index : a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30 : 519-524, 2012
PubMed
2) Imbriaco M, Larson SM, Yeung HW, et al : A new parameter for measuring metastatic bone involvement by prostate cancer : the Bone Scan Index. Clin Cancer Res 4 : 1765-1772, 1998
PubMed
3) Schmidmaier G, Wildemann B, Gabelein T, et al : Synergistic effect of IGF-I and TGFbeta 1 on fracture healing in rats : single versus combined application of IGF-I and TGF-beta 1. Acta Orthop Scand 74 : 604-610, 2003
 
4) Feely BT, Gamradt SC, Hsu WK, et al : Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20 : 2189-2199, 2005
 
5) Kitazawa S, Kitazawa R : RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198 : 228-236, 2002
PubMed
6) Dougall WC : Molecular pathways : Osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18 : 326-335, 2012
PubMed
7) Damle NA, Bal C, Bandopadhyaya GP, et al : The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma : a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol 31 : 262-269, 2013
PubMed
8) Nakahara T, Suzuki T, Kitamura N, et al : Bone scintigraphy is really unnecessary for evaluation of bone metastasis? Eur Radiol 18 : 2676-2677, 2008
PubMed
9) Utsunomiya D, Shiraishi S, Imuta M, et al : Added value of SPECT/CT fusion in assessing suspected bone metastasis : comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 238 : 264-271, 2006
PubMed
10) Mitsui Y, Shiina H, Yamamoto Y, et al : Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110 : E628-E634, 2012
PubMed
11) Zeintl J, Vija AH, Yahil A, et al : Quantitative accuracy of clinical 99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation and scatter correction. J Nucl Med 51 : 921-928, 2010
PubMed
12) Even-Sapir E, Metser U, Flusser G, et al : Assessment of malignant skeletal disease : initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45 : 272-278, 2004
PubMed
13) Even-Sapir E, Metser U, Mishani E, et al : The detection of bone metastases in patients with high-risk prostate cancer : 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47 : 287-297, 2006
PubMed
14) Jambor I, Kuisma A, Ramadan S, et al : Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients : SKELETA clinical trial. Acta Oncol. 2015 Apr 2 : 1-9. [Epub ahead of print]
 
P.180 掲載の参考文献
1) Tubiana-Hulin M : Incidence, prevalence and distribution of bone metastases. Bone 12 (Suppl. 1) : S9-10, 1991
 
2) Satoh T, Uemura H, Tanabe K, et al : A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castrationresistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy. Jpn J Clin Oncol 44 : 1206-1215, 2014
PubMed
3) Saad F, Shore N, Van Poppel H, et al : Impact of Bone-targeted Therapies in Chemotherapy-naive Metastatic Castrationresistant Prostate Cancer Patients Treated with Abiraterone Acetate : Post Hoc Analysis of Study COU-AA-302. Eur Urol 2015 [ Epub ahead of print]
 
4) 佐藤威文, 小林国彦, 堀泰祐, 他 : 骨転移がん患者に対するEORTC QOL調査モジュール : EORTC QLQ-BM22日本語版の開発. 癌と化学療法 37 : 1507-1512, 2010
Medical*Online
5) 国立がん研究センター統計資料 http://ganjoho.jp/public/index.html
 
6) Morris MJ, Akhurst T, Osman I, et al : Fluorinated deoxyglucose positron emission metastatic prostate cancer. Urology 59 : 913-918, 2002
PubMed
7) 日本泌尿器科学会編 : 前立腺癌診療ガイドライン 2012年版. 金原出版, 東京, 2012
 
8) 日本臨床腫瘍学会編 : 骨転移診療ガイドライン. 南山堂, 東京, 2015
 
9) 欧州泌尿器科学会 (EAU : European Association of Urology) ガイドライン 2015年度版 http://uroweb.org/guidelines/
 
10) National Comprehensive Cancer Network (NCCN) ガイドライン 2015年版 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
 
11) Scher HI : The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol 33 (Suppl ; abstr 5000) : 2015
 
12) Sakata T, Ferdous G, Tsuruta T, et al : L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59 : 7-18, 2009
PubMed
13) Yanagisawa N, Satoh T, Hana K, et al : L-amino acid transporter 1 may be a prostatic cancer under expectant management. Cancer Biomark 2015 [Epub ahead of print]
 
14) Asano Y, Inoue Y, Ikeda Y, et al : Phase I clinical study of NMK36 : a new PET tracer with the synthetic amino acid analogue anti [- 18F] FACBC. Ann Nucl Med 25 : 414-418, 2011
PubMed
15) Inoue Y, Asano Y, Satoh T, et al : Phase IIa Clinical Trial of Trans-1-Amino-3-18F-Fluoro-Cyclobutyl-Carboxylic Acid in Metastatic Prostate Cancer. Asia Oceania J Nucl Med Biol 2 : 87-94, 2014
 
16) Dennis ER, Jia X, Mezheritskiy IS, et al : Bone scan index : a quantitative treatment response biomarker for castrationresistant metastatic prostate cancer. J Clin Oncol 30 : 519-524, 2012
PubMed
P.189 掲載の参考文献
1) 日本臨床腫瘍学会編 : 骨転移診療ガイドライン. 南江堂, 東京, 2015
 
2) 森脇昭介, 万代光一, 山上啓太郎 : 癌の骨髄転移の病理形態と問題点. 病理と臨床 17 : 28-34, 1999
Medical*Online
3) Marx RE : Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws : a growing epidemic. J Oral Maxillofac Surg 61 : 1115-1117, 2003
PubMed
4) Ruggiero SL, Dodson TB, Fantasia J, et al : American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 update. J Oral Maxillofac Surg 72 : 1938-1956, 2014
 
5) Ikeda T, Kuraguchi J, Kogashiwa Y, et al : Successful treatment of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) patients with sitafloxacin : New strategies for the treatment of BRONJ. Bone 73 : 217-222, 2015
PubMed
6) Hoff AO, Toth BB, Altundag K, et al : Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 : 826-836, 2008
PubMed
7) Bamias A, Kastritis E, Bamia C, et al : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : incidence and risk factors. J Clin Oncol 23 : 8580-8587, 2005
PubMed
8) Woo SB, Hande K, Richardson PG : Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 : 99-102, 2005
PubMed
9) Fantasia JE : Bisphosphonates--what the dentist needs to know : practical considerations. J Oral Maxillofac Surg 67 (5 Suppl) : 53-60, 2009
 
P.200 掲載の参考文献
1) Coleman RE : Skeletal complications of malignancy. Cancer 80 : 1588-1594, 1997
PubMed
2) Coleman RE : Metastatic bone disease : clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 : 165-176, 2001
PubMed
3) Daniell HW, Dunn SR, Ferguson DW, et al : Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 : 181-186, 2000
PubMed
4) Beer TM, Armstrong AJ, Rathkopf DE, et al : PREVAIL Investigators : Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 31 : 424-433, 2014
 
5) Ryan CJ, Smith MR, de Bono JS, et al : Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 : 138-148, 2013
PubMed
6) Smith MR, Coleman RE, Klotz L, et al : Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer : comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26 : 368-374, 2015
PubMed
7) Shirley M, McCormack PL, et al : Radium-223 dichloride : a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 74 : 579-586, 2014
PubMed
8) Saad F, Gleason DM, Murray R, et al : Zoledronic Acid Prostate Cancer Study Group : A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 : 1458-1468, 2002
 
9) Lipton A, Jacobs I : Denosumab : benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care 5 : 258-264, 2011
PubMed
10) Saito M, Fujii K, Marumo K : Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79 : 160-168, 2006
PubMed
11) Saito M, Marumo K, Soshi S, et al : Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 21 : 655-666, 2010
PubMed
12) Kamiya N, Suzuki H, Endo T, et al : Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol 19 : 968-979, 2012
 
13) Oesterling JE, Martin SK, Bergstralh EJ, et al : The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 : 57-60, 1993
PubMed
14) Soloway MS, Hardeman SW, Hickey D, et al : Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 : 195-202, 1988
PubMed
15) Scher HI, Halabi S, Tannock I, et al : Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone : recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 : 1148-1159, 2008
 
16) Armstrong AJ, Febbo PG : Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer : an update and review of the literature. Oncologist 14 : 816-827, 2009
PubMed
17) Corrie D, Timmons JH, Bauman JM, et al : Efficacy of follow-up bone scans in carcinoma of the prostate. Cancer 61 : 2453-2454, 1988
PubMed
18) Oesterling JE, Martin SK, Bergstralh EJ, et al : The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269 : 57-60, 1993
PubMed
19) Kamiya N, Suzuki H, Yano M, et al : Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology 75 : 1446-1451, 2010
PubMed
20) Akimoto S, Furuya Y, Akakura K, et al : Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis : comparison with the extent of disease (EOD) grade. Prostate 38 : 28-34, 1999
 
21) Nakashima J, Sumitomo M, Miyajima A, et al : The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol 157 : 1736-1739, 1997
PubMed
22) Ozu C, Nakashima J, Horiguchi Y, et al : Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol 15 : 419-422, 2008
PubMed
23) Noguchi M, Noda S : Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166 : 1106-1110, 2001
PubMed
24) Hegele A, Wahl HG, Varga Z, et al : Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer. BJU Int 99 : 330-334, 2007
PubMed
25) Watts NB : Clinical utility of biochemical markers of bone remodeling. Clin Chem 45 : 1359-1368, 1999
PubMed
26) Gutman EB, Sproul EE, Gutman AB : Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28 : 485-495, 1936
 
27) Wymenga LF, Boomsma JH, Groenier K, et al : Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 88 : 226-230, 2001
PubMed
28) Armstrong AJ, Garrett-Mayer ES, Yang YC, et al : A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res 13 : 6396-6403, 2007
PubMed
29) Halabi S, Small EJ, Kantoff PW, et al : Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 : 1232-1237, 2003
PubMed
30) Hill CS, Wolfert RL : The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 186 : 315-320, 1989
PubMed
31) European Association of Urology guidelines : prostate cancer. 2014 ; http://uroweb.org/guideline/prostate-cancer/
PubMed
32) Taylor AK, Linkhart S, Mohan S, et al : Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 70 : 467-472, 1990
PubMed
33) Ivaska KK, Kakonen S-M, Gerdhem P, et al : Urinary osteocalcin as a marker of bone metabolism. Clin Chem 51 : 618-628, 2005
PubMed
34) Coleman RE : The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94 : 2521-2533, 2002
PubMed
35) Pectasides D, Farmakis D, Nikolaou M, et al : Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal 37 : 171-176, 2005
PubMed
36) Politou M, Terpos E, Nadal E, et al : Prolonged effect of reduced intensity conditioning (RIC) allogeneic transplantation for multiple myeloma on biochemical markers of bone remodeling and osteoclast function : report of a case. Haema 7 : 87-91, 2004
 
37) Coleman R, Brown J, Terpos E, et al : Bone markers and their prognostic value in metastatic bone disease : clinical evidence and future directions. Cancer Treat Rev 34 : 629-639, 2008
PubMed
38) Calvo MS, Eyre DR, Gundberg CM : Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17 : 333-368, 1996
PubMed
39) Blumsohn A, Herrington K, Hannon RA, et al : The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 79 : 730-735, 1994
PubMed
40) Jung K, Lein M, Stephan C, et al : Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread : diagnostic and prognostic implications. Int J Cancer 111 : 783-791, 2004
PubMed
41) Sassi ML, Eriksen H, Risteli L, et al : Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen : loss of antigenicity by treatment with cathepsin K. Bone 26 : 367-373, 2000
PubMed
42) Calvo MS, Eyre DR, Gundberg CM : Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 17 : 333-368, 1996
PubMed
43) Koopmans N, de Jong IJ, Breeuwsma AJ, et al : Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer : a longitudinal approach. J Urol 178 : 849-853, 2007
PubMed
44) Koga H, Naito S, Koto S, et al : Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 39 : 1-7, 1999
PubMed
45) Halleen JM : Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23 : 1027-1029, 2003
PubMed
46) Woitge HW, Pecherstorfer M, Li Y, et al : Novel serum markers of bone resorption : clinical assessment and comparison with established urinary indices. J Bone Miner Res 14 : 792-801, 1999
PubMed
47) Khosla S : the OPG/RANKL/RANK system. Endocrinology 142 : 5050-5055, 2001
PubMed
48) Mountzios G, Dimopoulos MA, Bamias A, et al : Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 46 : 221-229, 2007
 
49) Kamiya N, Suzuki H, Endo T, et al : Significance of serum osteoprotegerin and receptor activator of nuclear factorκB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol 16 : 366-372, 2011
 
50) Saad F, Gleason DM, Murray R, et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
PubMed
51) Rosen LS, Gordon D, Tchekmedyian NS, et al : Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100 : 2613-2621, 2004
PubMed
52) Rosen LS, Gordon D, Kaminski M, et al : Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : a randomized, double-blind, multicenter, comparative trial. Cancer 98 : 1735-1744, 2003
PubMed
53) National Comprehensive Cancer Network guideline : prostate cancer. version 1. 2015 ; http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdff
 
54) Fournier P, Boissier S, Filleur S, et al : Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 : 6538-6544, 2002
PubMed
55) Santini D, Vincenzi B, Dicuonzo G, et al : Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9 : 2893-2897, 2003
PubMed
56) Santini D, Martini F, Fratto ME, et al : In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 58 : 31-38, 2009
PubMed
57) Coxon JP, Oades GM, Kirby RS, et al : Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 94 : 164-170, 2004
PubMed
58) Fizazi K, Carducci M, Smith M, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
59) Cook RJ, Coleman R, Brown J, et al : Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res 12 : 3361-3367, 2006
PubMed
60) Lipton A, Cook R, Saad F, et al : Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113 : 193-201, 2008
 
61) Brown JE, Cook RJ, Major P, et al : Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 : 59-69, 2005
PubMed
62) Lein M, Wirth M, Miller K, et al : Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. Eur Urol 52 : 1381-1387, 2007
PubMed
63) Smith MR, Egerdie B, Hernandez Toriz N, et al : Denosumab HALT Prostate Cancer Study Group : Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361 : 745-755, 2009
 
64) NIH consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy Osteoporosis prevention, diagnosis and therapy. JAMA 285 : 785-795, 2001
PubMed
65) 斎藤充, 丸毛啓史 : 骨強度の規定因子の多様性における骨密度と骨質の関与. THE BONE 25 : 25-32, 2011
Medical*Online
66) Saito M, Marumo K : Collagen cross-links as a determinant of bone quality : a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21 : 195-214, 2010
PubMed
67) Saito M, Marumo K, Fujii K, et al : Single-column high-performance liquid chromatographic-fluorescence detection of immature, mature, and senescent cross-links of collagen. Anal Biochem 253 : 26-32, 1997
PubMed
68) Saito M, Marumo K, Ushiku C, et al : Effects of alfacalcidol on mechanical properties and collagen cross-links of the femoral diaphysis in glucocorticoid-treated rats. Calcif Tissue Int 88 : 314-324, 2011
PubMed
69) Imbriaco M, Larson SM, Yeung HW, et al : A new parameter for measuring metastatic bone involvement by prostate cancer : the Bone Scan Index. Clin Cancer Res 4 : 1765-1772, 1998
PubMed
P.210 掲載の参考文献
1) Leibovici D, Spiess PE, Agarwal PK, et al : Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109 : 198-204, 2007
PubMed
2) Soloway MS, Hardeman SW, Hickey D, et al : Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 : 195-202, 1988
PubMed
3) Sabbatini P, Larson SM, Kremer A, et al : Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17 : 948-957, 1999
PubMed
4) Ulmert D, Kaboteh R, Fox JJ, et al : A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62 : 78-84, 2012
PubMed
5) Reza M, Bjartell A, Ohlsson M, et al : Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Res 4 : 58, 2014
PubMed
6) Meirelles GS, Schoder H, Ravizzini GC, et al : Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res 16 : 6093-6099, 2010
PubMed
7) Kaboteh R, Damber JE, Gjertsson P, et al : Bone Scan Index : a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res 3 : 9, 2013
PubMed
8) Dennis ER, Jia X, Mezheritskiy IS, et al : Bone scan index : a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30 : 519-524, 2012
PubMed
9) Mitsui Y, Shiina H, Yamamoto Y, et al : Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110 : E628-634, 2012
PubMed
10) Kaboteh R, Gjertsson P, Leek H, et al : Progression of bone metastases in patients with prostate cancer-automated detection of new lesions and calculation of bone scan index. EJNMMI Res 3 : 64, 2013
PubMed
11) Even-Sapir E, Metser U, Mishani E, et al : The detection of bone metastases in patients with high-risk prostate cancer : 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47 : 287-297, 2006
PubMed
12) Ryan CJ, Shah S, Efstathiou E, et al : Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17 : 4854-4861, 2011
PubMed
13) Scher HI, Eisenberger M, D'Amico AV, et al : Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen : recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22 : 537-556, 2004
 
P.221 掲載の参考文献
1) Bubendorf L, Schopfer A, Wagner U, et al : Metastatic patterns of prostate cancer : an autopsy study of 1,589 patients. Hum Pathol 31 : 578-583, 2000
PubMed
2) Erdi YE, Humm JL, Imbriaco M, et al : Quantitative bone metastases analysis based on image segmentation. J Nucl Med 38 : 1401-1406, 1997
PubMed
3) Imbriaco M, Larson SM, Yeung HW, et al : A new parameter for measuring metastatic bone involvement by prostate cancer : the Bone Scan Index. Clin Cancer Res 4 : 1765-1772, 1998
PubMed
4) Sadik M, Suurkula M, Hoglund P, et al : Quality of planar whole-body bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging 35 : 1464-1472, 2008
PubMed
5) Sadik M, Suurkula M, Hoglund P, et al : Improved classifications of planar wholebody bone scans using a computerassisted diagnosis system : a multicenter, multiple-reader, multiple-case study. J Nucl Med 50 : 368-375, 2009
PubMed
6) Sabbatini P, Larson SM, Kremer A, et al : Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17 : 948-957, 1999
PubMed
7) Sadik M, Hamadeh I, Nordblom P, et al : Computer-Assisted Interpretation of Planar Whole-Body Bone Scans. J Nucl Med 49 : 1958-1965, 2008
PubMed
8) Sadik M, Jakobsson D, Olofsson F, et al : A new computer-based decision-support system for the interpretation of bone scans. Nucl Med Commun 27 : 417-423, 2006
PubMed
9) David U, Kaboteh R, Fox JJ, et al : A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62 : 78-84, 2012
 
10) Horikoshi H, Kikuchi A, Onoguchi M, et al : Computer-aided diagnosis system for bone scintigrams from Japanese patients : importance of training database. Ann Nucl Med 26 : 622-626, 2012
PubMed
11) Nakajima K, Nakajima Y, Horikoshi H, et al : Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system : a Japanese multicenter database project. EJNMMI Res 26 : 83, 2013
 
12) Brown MS, Chu GH, Kim HJ, et al : Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun 33 : 384-394, 2012
PubMed
13) Soloway MS, Hardeman SW, Hickey D, et al : Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 : 195-202, 1988
PubMed
14) Jorgensen T, Muller C, Kaalhus O, et al : Extent of disease based on initial bone scan : important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No.2 (SPCG-2). Eur Urol 28 : 40-46, 1995
 
15) Eisenhauer EA, Therasse P, Bogaerts J, et al : New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45 : 228-247, 2009
PubMed
16) Dennis ER, Jia X, Mezheritskiy IS, et al : Bone scan index : a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30 : 519-524, 2012
PubMed
17) Mitsui Y, Shiina H, Yamamoto Y, et al : Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 110 (11 Pt B) : E628-634, 2012
 
18) Saylor PJ, Mahmood U, Kunawudhi A, et al : Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers : Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 53 : 1670-1675, 2012
PubMed
19) Wakabayashi H, Nakajima K, Mizokami A, et al : Bone scintigraphy as a new imaging biomarker : the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med 27 : 802-807, 2013
PubMed

V. 骨転移病変の治療

P.236 掲載の参考文献
1) Inoue T, Segawa T, Kamba T, et al : Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 73 : 1104-1109, 2009
PubMed
2) 武田文和 : 癌性疼痛のコントロール. 檀健二郎, 横田敏勝編, 南江堂, 東京, pp.66-83, 1993
 
3) Pecher C : Biological investigation with radioactive calcium and strontium : preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. Pharmacol 11 : 117-149, 1942
 
4) Robinson RG, Spicer JA, Preston DF, et al : Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 14 : 219-222, 1987
 
5) Ackery D, Yardley J : Radionuclidetargeted therapy for the management of metastatic bone pain. Semin Oncol 20 : 27-31, 1993
PubMed
6) Siegel HJ, Luck JV Jr, Siegel ME : Advances in radionuclide therapeutics in orthopaedics. J Am Acad Orthop Surg 12 : 55-64, 2004
PubMed
7) Blake GM, Zivanovic MA, Blaquiere RM, et al : Strontium-89 therapy : measurement of absorbed dose to skeletal metastases. J Nucl Med 29 : 549-557, 1988
PubMed
8) Ben-Josef E, Maughan RL, Vasan S, et al : A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun 16 : 452-456, 1995
 
9) Robinson RG, Peston DF, Schiefelbein M, et al : Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 274 : 420-424, 1995
 
10) Kan Michael K : Palliation of bone pain in patients with metastatic cancer using strontium-89 (Metastron). Cancer Nurs 18 : 286-291, 1995
 
11) Finlay IG, Mason MD, Shelley M : Radioisotopes for the palliation of metastatic bone cancer : a systematic review. Lancet Oncol 6 : 392-340, 2005
PubMed
12) 西尾正道, 佐野宗明, 玉木義雄, 他 : 疼痛を伴う骨転移癌患者の疼痛緩和に対する塩化ストロンチウム (Sr-89) (SMS.2P) の有効性及び安全性を評価する多施設共同オープン試験. 日医放会誌 65 : 399-410, 2005
 
13) 木村良子, 濱本研, 鈴木謙三, 他 : 転移性骨腫瘍に伴う骨性疼痛に対する放射性ストロンチウム (89Sr) 製剤SMS. 2Pの第2相臨床試験. 核医学 32 : 311-321, 1995
 
14) Baranauskas Z, Valuckas K, Aleknavicius E, et al : Use of strontium-89 in the analgesic treatment of cancer patients with bone metastases. Medicina 42 : 11-14, 2006
PubMed
15) Storto G, Klain M, Paone G, et al : Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39 : 35-41, 2006
PubMed
16) Kuroda I : Effective use of strontium-89 in osseous metastases. Ann Nucl Med 26 : 197-206, 2012
PubMed
17) Silberstein EB : Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 35 : 152-158, 2005
PubMed
18) Dafermou A, Colamussi P, Giganti M, et al : A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28 : 788-798, 2001
PubMed
19) Laing AH, Ackery DM, Bayly RJ, et al : Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64 : 816-822, 1991
PubMed
20) Windsor PM : Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer : report of a single centre's 10-year experience. Clin Oncol 13 : 219-227, 2001
PubMed
21) Zyskowski A, Lamb D, Morum P, et al : Strontium-89 treatment for prostate cancer bone metastases : does a prostate-specific antigen response predict for improved survival? Australas Radiol 45 : 39-42, 2001
PubMed
22) Kuroda I : Strontium-89 for prostate cancer with bone metastases : the potential of cancer control and improvement of overall survival. Ann Nucl Med 28 : 11-16, 2014
PubMed
23) 恒藤暁, 池永昌之, 細井順, 他 : 末期がん患者の現状に関する研究. ターミナルケア 6 : 482-490, 1996
 
24) 黒田功 : 89Srをより有効に処方するコツ 臨床経験をふまえて. 臨床放射線 56 : 975-982, 2011
 
25) Quilty PM, Kirk D, Bolger JJ, et al : A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31 : 33-40, 1994
PubMed
P.245 掲載の参考文献
1) Fujimoto H, Nakanishi H, Miki T, et al : Oncological outcomes of the prostate cancer patients registered in 2004 : report from the Cancer Registration Committee of the JUA. Int J Urol 18 : 876-881, 2011
PubMed
2) Sgouros G, Ballangrud AM, Jurcic JG, et al : Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody : 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 40 : 1935-1946, 1999
PubMed
3) Finlay IG, Mason MD, Shelley M : Radioisotopes for the palliation of metastatic bone cancer : a systematic review. Lancet Oncol 6 : 392-400, 2005
PubMed
4) Wissing MD, van Leeuwen FW, van der Pluijm G, et al : Radium-223 chloride : Extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res 19 : 5822-5827, 2013
 
5) Turner SL, Gruenewald S, Spry N, et al : Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84 : 297-302, 2001
PubMed
6) Buchali K, Correns HJ, Schuerer M, et al : Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14 : 349-351, 1988
PubMed
7) Nilsson S, Larsen RH, Fossa SD, et al : First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11 : 4451-4459, 2005
PubMed
8) Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al : Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 40 : 1384-1393, 2013
PubMed
9) Nilsson S, Franzen L, Parker C, et al : Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer : a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8 : 587-594, 2007
PubMed
10) Nilsson S, Strang P, Aksnes AK, et al : A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 48 : 678-686, 2012
PubMed
11) Parker C, Nilsson S, Heinrich D, et al : Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 : 213-223, 2013
PubMed
12) Hoskin P, Sartor O, O'Sullivan JM, et al : Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use : a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15 : 1397-1406, 2014
 
13) Parker C, Vogelzang NJ, Sartor O, et al : 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. 2015 Genitourinary Cancers Symposium. Abstract #195
 
P.255 掲載の参考文献
1) Klish DS, Grossman P, Allen PK, et al : Irradiation of spinal metastases : should we continue to include one uninvolved vertebral body above and below in the radiation field? Int J Radiat Oncol Biol Phys 81 : 1495-1499, 2011
PubMed
2) Lutz S, Berk L, Chang E, et al : Palliative radiotherapy for bone metastases : an astro evidence-based guideline. Int J Radiat Oncol Biol Phys 79 : 965-976, 2011
PubMed
3) Wu JS, Wong R, Johnston M, et al : Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55 : 594-605, 2003
PubMed
4) Hoskin PJ, Yarnold JR, Roos DR, et al ; Second Workshop on Palliative Radiotherapy and Symptom Control : Radiotherapy for bone metastases. Clin Oncol (R Coll Radiol) 13 : 88-90, 2001
PubMed
5) Chow E, Harris K, Fan G, et al : Palliative radiotherapy trials for bone metastases : A systematic review. J Clin Oncol 25 : 1423-1436, 2007
 
6) Sze WM, Shelley M, Held I, et al : Palliation of metastatic bone pain : single fraction versus multifraction radiotherapy-a systematic review of the randomised trials. Cochrane Database Syst Rev 2004 : Cd004721
PubMed
7) Steenland E, Leer JW, van Houwelingen H, et al : The effect of a single fraction compared to multiple fractions on painful bone metastases : a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52 : 101-109, 1999
PubMed
8) Loblaw DA, Wu JS, Kirkbride P, et al : Pain flare in patients with bone metastases after palliative radiotherapy--a nested randomized control trial. Suppor Care Cancer 15 : 451-455, 2007
 
9) Chow E, Ling A, Davis L, et al : Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol 75 : 64-69, 2005
PubMed
10) Kirou-Mauro A, Hird A, Wong J, et al : Is response to radiotherapy in patients related to the severity of pretreatment pain? Int J Radiat Oncol Biol Phys 71 : 1208-1212, 2008
 
11) Arcangeli G, Giovinazzo G, Saracino B, et al : Radiation therapy in the management of symptomatic bone metastases : The effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42 : 1119-1126, 1998
PubMed
12) Party BPTW : 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain : randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52 : 111-121, 1999
 
13) Hartsell WF, Scott CB, Bruner DW, et al : Randomized trial of short- versus longcourse radiotherapy for palliation ofpainful bone metastases. J Natl Cancer Inst 97 : 798-804, 2005
PubMed
14) Chow E, Zeng L, Salvo N, et al : Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 24 : 112-124, 2012
PubMed
15) Nakamura N, Shikama N, Wada H, et al : Patterns of practice in palliative radiotherapy for painful bone metastases : a survey in Japan. Int J Radiat Oncol Biol Phys 83 : e117-120, 2012
PubMed
16) Lo SS, Holden L, Lutz ST, et al : Should all patients with uncomplicated bone metastases be treated with a single 8-Gy fraction? Expert Rev Pharmacoecon Outcomes Res 10 : 95-98, 2010
PubMed
17) Roos DE, Turner SL, O'Brien PC, et al : Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 75 : 54-63, 2005
 
18) Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, et al : Strontium-89 (metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 29 : 494-498, 2002
 
19) van der Linden YM, Kroon HM, Dijkstra SP, et al : Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions : results from a randomised trial. Radiother Oncol 69 : 21-31, 2003
PubMed
20) Chow E, Wu JS, Hoskin P, et al : International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64 : 275-280, 2002
PubMed
21) Kaasa S, Brenne E, Lund JA, et al : Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy×1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol 79 : 278-284, 2006
 
22) Tong D, Gillick L, Hendrickson FR : The palliation of symptomatic osseous metastases : Final results of the study by the radiation therapy oncology group. Cancer 50 : 893-899, 1982
 
23) Price P, Hoskin PJ, Easton D, et al : Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6 : 247-255, 1986
PubMed
24) Loblaw DA, Laperriere NJ : Emergency treatment of malignant extradural spinal cord compression : an evidence-based guideline. J Clin Oncol 16 : 1613-1624, 1998
PubMed
25) Maranzano E, Latini P : Effectiveness of radiation therapy without surgery in metastatic spinal cord compression : final results from a prospective trial. Int J Radiat Oncol Biol Phys 32 : 959-967, 1995
PubMed
26) White BD, Stirling AJ, Paterson E, et al : Diagnosis and management of patients at risk of or with metastatic spinal cord compression : summary of NICE guidance. BMJ (Clinical research ed.) 337 : a2538, 2008
PubMed
27) Zaidat OO, Ruff RL : Treatment of spinal epidural metastasis improves patient survival and functional state. Neurology 58 : 1360-1366, 2002
PubMed
28) Maranzano E, Latini P, Beneventi S, et al : Comparison of two different radiotherapy schedules for spinal cord compression in prostate cancer. Tumori 84 : 472-477, 1998
PubMed
29) Sorensen S, Helweg-Larsen S, Mouridsen H, et al : Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy : a randomised trial. Eur J Cancer (Oxford, England : 1990) 30a : 22-27, 1994
 
30) Heimdal K, Hirschberg H, Slettebo H, et al : High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 12 : 141-144, 1992
PubMed
31) Graham PH, Capp A, Delaney G, et al : A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy : Trog 01.05 superdex study. Clin Oncol (R Coll Radiol) 18 : 70-76, 2006
 
32) Vecht CJ, Haaxma-Reiche H, van Putten WL, et al : Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 39 : 1255-1257, 1989
PubMed
33) L'Esperance S, Vincent F, Gaudreault M, et al : Treatment of metastatic spinal cord compression : cepo review and clinical recommendations. Curr Oncol 19 : e478-490, 2012
 
34) Maranzano E, Latini P, Beneventi S, et al : Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase ii trial. Am J Clin Oncol 19 : 179-183, 1996
 
35) Fisher CG, DiPaola CP, Ryken TC, et al : A novel classification system for spinal instability in neoplastic disease : An evidence-based approach and expert consensus from the spine oncology study group. Spine 35 : E1221-1229, 2010
 
36) Fourney DR, Frangou EM, Ryken TC, et al : Spinal instability neoplastic score : An analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29 : 3072-3077, 2011
 
37) Patchell RA, Tibbs PA, Regine WF, et al : Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer : a randomised trial. Lancet 366 : 643-648, 2005
PubMed
38) Loblaw DA, Mitera G, Ford M, et al : A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 84 : 312-317, 2012
 
39) Rades D, Stalpers LJ, Schulte R, et al : Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. Eur J Cancer 42 : 1052-1056, 2006
PubMed
40) Rades D, Karstens JH, Hoskin PJ, et al : Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 67 : 525-531, 2007
PubMed
41) Rades D, Walz J, Stalpers LJ, et al : Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma : results of a retrospective multi-center study. Eur Urol 49 : 846-852, 2006 ; discussion 852
PubMed
42) Rades D, Stalpers LJ, Veninga T, et al : Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 23 : 3366-3375, 2005
PubMed
43) Rades D, Lange M, Veninga T, et al : Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. Int J Radiat Oncol Biol Phys 73 : 228-234, 2009
PubMed
44) Huisman M, van den Bosch MA, Wijlemans JW, et al : Effectiveness of reirradiation for painful bone metastases : a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 84 : 8-14, 2012
PubMed
45) Bedard G, Hoskin P, Chow E : Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment. Radiother Oncol 112 : 125-127, 2014
PubMed
46) Nieder C, Grosu AL, Andratschke NH, et al : Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys 66 : 1446-1449, 2006
PubMed
47) Mithal NP, Needham PR, Hoskin PJ : Retreatment with radiotherapy for painful bone metastases. Int J Radiat Oncol Biol Phys 29 : 1011-1014, 1994
PubMed
48) Wong CS, Van Dyk J, Milosevic M, et al : Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 30 : 575-581, 1994
PubMed
49) van der Linden YM, Lok JJ, Steenland E, et al : Single fraction radiotherapy is efficacious : a further analysis of the Dutch bone metastasis study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 59 : 528-537, 2004
PubMed
50) Jeremic B, Shibamoto Y, Igrutinovic I : Single 4 Gy re-irradiation for painful bone metastasis following single fraction radiotherapy. Radiother Oncol 52 : 123-127, 1999
PubMed
51) Chow E, van der Linden YM, Roos D, et al : Single versus multiple fractions of repeat radiation for painful bone metastases : A randomised, controlled, non-inferiority trial. Lancet Oncol 15 : 164-171, 2014
PubMed
52) Chow E, Meyer RM, Chen BE, et al : Impact of reirradiation of painful osseous metastases on quality of life and function : a secondary analysis of the NCIC CTG SC.20 randomized trial. J Clin Oncol 32 : 3867-3873, 2014
 
53) van der Sande JJ, Boogerd W, Kroger R, et al : Recurrent spinal epidural metastases : a prospective study with a complete follow up. J Neurol Neurosurg Psychiatry 66 : 623-627, 1999
PubMed
54) Maranzano E, Trippa F, Casale M, et al : Reirradiation of metastatic spinal cord compression : definitive results of two randomized trials. Radiother Oncol 98 : 234-237, 2011
PubMed
55) Yamada Y, Lovelock DM, Yenice KM, et al : Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors : a preliminary report. Int J Radiat Oncol Biol Phys 62 : 53-61, 2005
PubMed
56) Garg AK, Wang XS, Shiu AS, et al : Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy : The University of Texas MD Anderson Cancer Center experience. Cancer 117 : 3509-3516, 2011
PubMed
57) Hall WA, Stapleford LJ, Hadjipanayis CG, et al : Stereotactic body radiosurgery for spinal metastatic disease : an evidence-based review. Int J Surg Oncol 2011 : 979214, 2011
PubMed
58) Sahgal A, Bilsky M, Chang EL, et al : Stereotactic body radiotherapy for spinal metastases : current status, with a focus on its application in the postoperative patient. J Neurosurg Spine 14 : 151-166, 2011
 
59) Cunha MV, Al-Omair A, Atenafu EG, et al : Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT) : analysis of predictive factors. Int J Radiat Oncol Biol Phys 84 : e343-349, 2012
PubMed
60) Rose PS, Laufer I, Boland PJ, et al : Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27 : 5075-5079, 2009
PubMed
61) Sahgal A, Whyne CM, Ma L, et al : Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol 14 : e310-320, 2013
PubMed
P.267 掲載の参考文献
1) Aaron AD : Treatment of metastatic adenocarcinoma of the pelvis and the extremities. J Bone Joint Surg Am 80 : 763-764, 1998
 
2) Harrington KD, Sim FH, Enis JE, et al : Methylmethacrylate as an adjunct in internal fixation or pathological fractures. Experience with three hundred and seventy-five cases. J Bone Joint Surg Am 58 : 1047-1055, 1976
PubMed
3) Mirels H : Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 249 : 256-264, 1989
 
4) Hipp JA, Springfield DS, Hayes WC : Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop 249 : 256-264, 1989
 
5) 山本憲男, 土屋弘行, 富田勝郎 : 髄内釘使用による転移性大腿骨腫瘍の治療成績. 整形外科 51 : 1506-1510, 2000
 
6) 山本憲男, 土屋弘行, 富田勝郎 : Kotz下肢再建システム使用時の股関節外転筋力温存の工夫. 臨整外 35 : 983-987, 2000
 
7) 丹沢義一, 白井寿治, 林克洋, 他 : 液体窒素処理自家骨を用いた転移性骨腫瘍切除後再建術. 整・災外 54 : 83-90, 2011
 
8) Nishida H, Shirai T, Hayashi K, et al : Cryotreatment against metastatic renal cell bone tumour reduced multiple lung metastases. Anticancer Res 31 : 2927-2930, 2011
PubMed
9) Chen TC : Prostate Cancer and Spinal cord compression. Oncology 15 : 841-855, 2001
PubMed
10) Murakami H, Kato S, Demura S, et al : Novel reconstruction technique using a frozen tumor-bearing vertebra from a total en bloc sponydylectomy for spinal tumors. Orthopedics 38 : 605-607, 2013
 
11) 荒木信人 : 転移性骨腫瘍診療に関する日本整形外科学会認定研修施設に対するアンケート調査結果報告. 日整会誌 79 : 526-533, 2005
Medical*Online
12) 荒木信人 : 転移性骨腫瘍. 外科 67 : 936-941, 2005
 

VI. 診療科横断的な骨転移診療体制 - 東京大学病院骨転移キャンサーボード -

P.279 掲載の参考文献
1) がん情報サービス 国立がん研究センターがん対策情報センターホームページ
 
2) Whitmore WF Jr : Natural history and staging of prostate cancer. Urol Clin North Am 11 : 205-220, 1984
PubMed
3) 厚生労働省がん研究助成金がんの骨転移に対する予後予測方法の確立と集学的治療法の開発班 編 : 骨転移治療ハンドブック. 金原出版, 東京, 2004
 
4) William GW, Stephanie H, Frederick J, et al : Metastatic Disease of the Femur : Surgical Treatment. Clin Orthop Releat Res 415S : S230-244, 2003
 
5) Bickels J, Dadia S, Lidar Z : Surgical management of metastatic bone disease. J Bone Jt Surg Am 91 : 1503-1516, 2009
 
6) Loblaw DA, Perry J, Chambers A, et al : Systematic review of the diagnosis and management of malignant extradural spinal cord compression : the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 23 : 2028-2037, 2005
 
7) 厚生労働省 : 終末期医療に関する調査等検討会報告書-今後の終末期医療の在り方について-. 平成16年7月
 
8) 厚生労働省 : 平成21年人口動態統計
 

VII. 前立腺癌と地域医療連携

P.296 掲載の参考文献
1) 日本クリニカルパス学会 : クリニカルパスの普及・体制の現状と課題～第14回 (平成26年) アンケート結果から～. 日クリニカルパス会誌 17 : 73-82, 2015
 
2) 鈴木健彦 : わが国のがん対策の歩みと課題 がん地域連携クリティカルパス-がん医療連携とコーディネート機能-. 日本医療マネジメント学会監修, pp.3-16, じほう, 東京, 2010
 
3) 谷水正人, 他 : 厚生労働科学研究費補助金がん臨床研究事業 全国のがん診療連携拠点病院において活用が可能な地域連携クリティカルパスモデルの開発に関する研究. 平成22年度総括・分担研究報告書, 2011
 
4) 岡崎正巳 : 病-診でつくる都心部の地域医療ネットワーク 患者の在宅ニーズに応えて. 看護管理 17 : 54-60, 2007
 
5) 田中良典 : 前立腺がん パスでできる! がん診療の地域連携と患者サポート. 岡田晋吾, 谷水正人編, pp.89-99, 医学書院, 東京, 2009
 
6) 田中良典 : 前立腺がん がん地域連携クリティカルパス-がん医療連携とコーディネート機能-. 日本医療マネジメント学会監修, pp.162-179, じほう, 東京, 2010
 
7) 平野恭弘 : 前立腺癌診療連携を成功させるポイント. Cancer Forum, 2-7, 2011
 
8) 井口厚司 : 前立腺がんにおける地域医療連携. Cancer Forum, 2-7, 2008
 
9) 赤倉功一郎, 松崎香奈子, 中島敏彦, 他 : PSA高値の前立腺がん疑い患者を対象とした地域連携クリティカルパス. 医療マネジメント会誌 8 : 381-385, 2007
Medical*Online
10) 植田健, 浜野公明, 佐塚智和, 他 : 泌尿器がんの地域連携クリティカルパス. 医療マネジメント会誌 10 : 420-425, 2009
Medical*Online
11) 井口厚司 : 連携医の専門性の違いによる前立腺がん地域連携への影響. 医療マネジメント会誌 12 : 8-13, 2011
Medical*Online
12) 田中良典 : 武蔵野・三鷹地域における前立腺がん地域連携. NEOSYS 2 : 4-5, 2012
 
13) 清家健作, 前田真一 : 前立腺がん内分泌治療中の患者を対象とした地域連携クリティカルパス. 医療マネジメント会誌 10 : 506-509, 2009
Medical*Online
14) 下村裕見子, 池田俊也, 武藤正樹, 他 : がん診療連携拠点病院等におけるがん地域連携クリニカルパス稼動調査と連携体制の課題. 日クリニカルパス会誌 13 : 98-104, 2011
 
15) 浜野公明, 他 : 質の高い医療連携に向けて地域医療連携室の果たす役割. Cancer Forum, 2-7, 2010
 
16) 骨粗鬆症の予防と治療ガイドライン作成委員会編 : 骨粗鬆症の予防と治療ガイドライン 2011年版. pp.118-119, ライフサイエンス出版, 東京, 2011
 
17) 乳がん治療に伴う骨粗鬆症 骨粗鬆症・乳癌治療のエキスパートの立場から. Medical Tribune, 2012年10月25日号
 
18) 日本泌尿器科学会編 : 前立腺癌診療ガイドライン 2012年版. pp.202, 金原出版, 東京, 2012
 
19) 上村博司 : 前立腺癌治療と骨マネジメント. RANMARK Symposium 2014, 2014
 
20) 宮腰尚久, 山本智章, 萩野浩, 他 : 大腿骨頚部 (近位部) 骨折地域連携クリティカルパスの実態に関する全国調査. 日整学誌 86 : 913-920, 2012
 
21) 骨粗鬆症治療のアドヒアランス向上の地域医療連携. Medical Tribune, 2012年11月15日号
 
22) 骨粗鬆症マネージャーレクチャーコース (リエゾンサービス) ホームページ http://shinsen.biz/ols2012/〔2015.03.11〕
 

VIII. 骨転移診療ガイドラインについて

P.304 掲載の参考文献
1) Kodaira M, Takahashi S, Yamada S, et al : Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 21 : 1163-1167, 2010
PubMed
2) Patchell RA, Tibbs PA, Regine WF, et al : Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer : a randomised trial. Lancet 366 : 643-648, 2005
PubMed
3) Chow E, Zeng L, Salvo N, et al : Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Onco (l R Coll Radiol) 24 : 112-124, 2012
 
4) D'Angelo G, Sciuto R, Salvatori M, et al : Targeted "bone-seeking" radiopharmaceuticals for palliative treatment of bone metastases : a systematic review and meta-analysis. Q J Nucl Med Mol Imaging 56 : 538-543, 2012
PubMed
5) Hortobagyi GN, Theriault RL, Porter L, et al : Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 : 1785-1791, 1996
 
6) Berenson JR, Lichtenstein A, Porter L, et al : Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group [see comments]. N Engl J Med 334 : 488-493, 1996
 
7) Kohno N, Aogi K, Minami H, et al : Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer : a randomized, placebo-controlled trial. J Clin Oncol 23 : 3314-3321, 2005
 
8) Rosen LS, Gordon D, Tchekmedyian S, et al : Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21 : 3150-3157, 2003
 
9) Saad F, Gleason DM, Murray R, et al : Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 96 : 879-882, 2004
PubMed
10) Stopeck AT, Lipton A, Body JJ, et al : Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol 28 : 5132-5139, 2010
PubMed
11) Henry DH, Costa L, Goldwasser F, et al : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29 : 1125-1132, 2011
PubMed
12) Fizazi K, Carducci M, Smith M, et al : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 377 : 813-822, 2011
PubMed
13) Takahashi S, Iwase T, Kohno N, et al : Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole : 12-month results. Breast Cancer Res Treat 133 : 685-693, 2012
PubMed
14) Gnant M, Pfeiler G, Dubsky PC, et al : Adjuvant denosumab in breast cancer (ABCSG-18) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386 : 433-443, 2015
PubMed
15) Early Breast Cancer Trialists' Collaborative G : Adjuvant bisphosphonate treatment in early breast cancer : meta-analyses of individual patient data from randomised trials. Lancet, 2015 Jul 23. pii : S0140-6736 (15) 60908-4.
 
16) Smith MR, Saad F, Coleman R, et al : Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial. Lancet 379 : 39-46, 2012
PubMed

IX. 多職種で取り組む骨粗鬆症診療 - 骨粗鬆症リエゾンサービスの意義と実践 -

P.310 掲載の参考文献
1) 骨粗鬆症の予防と治療ガイドライン作成委員会編集 : 骨粗鬆症の予防と治療ガイドライン 2015年版. ライフ・サイエンス出版, 東京, 2015
 
2) McLellam AR, Wolowacz SE, Zimovetz EA, et al : Fracture liaison services for the evaluation and management of patients with osteoporotic fracture : a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22 : 2083-2098, 2011
 
3) Huntjems KM, van Geel TA, van den Bergh JP, et al : Fracture liaison service : impact on subsequent non vertebral fracture incidence and mortality. J Bone Joint Surg Am 96 : e29, 2014
 
4) Van der Kallen J, Giles M, Cooper K, et al : A fracture prevention service reduces further fractures two years after incident minimal trauma fractures. Int J Rheuma Dis 17 : 195-203, 2014
 
5) Lih A, Nandapalan H, Kim M, et al : Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures : a 4-year prospective controlled study. Osteoporos Int 22 : 840-858, 2011
 
6) Mitchell PJ : Fracture liaison services : the UK experience. Osteoporos Int 22 (Suppl. 3) : S487-S494, 2011
 
7) Majumdar SB, Lier DA, Beaupre LA, et al : Osteoporosis case manager for patients with hip fractures : results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med 169 : 25-31, 2009
 
8) 日本骨粗鬆症学会 ホームページ
 
9) 中村利孝監修, 萩野浩, 細井孝之編 : わかる, できる! 骨粗鬆症リエゾンサービス. 医薬ジャーナル社, 東京, 2013
 

書評

最近チェックした商品履歴

Loading...